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BACKGROUND
Breast cancer is the most common cancer among women. 20–40% of breast 
cancers recur after initial treatment. Breast cancer has an unusual propensity of late 
recurrence even after decades of clinically undetectable disease. The biology behind 
this phenomenon of tumor silency, or tumor dormancy, is still poorly understood. 
There are currently no reliable tools to identify and therapeutically target a dormant 
breast cancer in its quiescent non-progressing state for preventing its recurrence.
To	 gain	 insight	 into	 the	 phenomen	 of	 tumor	 dormancy,	 various	 scientific	
approaches have been used, including animal models, cell culture studies, genetic 
and epidemiological investigations. Mathematical models have also been created 
to predict the progress of the disease. 
The aim of this study was to analyze whether early and late relapsing breast 
cancers differ in their expression pattern of selected biomarkers, and whether the 
expression differs in relation to clinicopathological parameters.
This analysis is based on immunohistochemical (IHC) demonstration of the 
expression of different antigens in surgically removed breast cancer tissues. The 
expression levels of different biomarkers were compared between early- and late-
relapsing breast cancers. Analysis of these differences may provide additional 
information for understanding the phenomenon of tumor dormancy in breast 
cancer.
METHODS
Metastatic	breast	cancers	were	identified	from	the	database	of	the	Department	of	
Pathology, University of Helsinki (QPati database). The tumors were divided into 
three categories according to the time of recurrence after the initial intervention. 
Of 73 primary tumors, 19 had relapsed before 2 years, 33 after 5 to 10 years, and 
21	after	10	years	from	the	treatment	of	the	primary	cancer.	The	paraffin-embedded	
tissue	or	paraffin	blocks	from	the	metastatic	tumors	and	their	corresponding	primary	
tumors were collected from the archives of the Department of Pathology/HUSLAB. 
Nine antibodies against proteins known to have a prognostic role in breast cancer 
were evaluated by IHC. These nine markers included the glycoprotein hormones 
stanniocalcin 1 (STC-1) and stanniocalcin 2 (STC-2), the mammary serin protease 
10
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inhibitor maspin, the antiapoptotic factor Bcl-2, the mutated oncoprotein product 
p53, the transcription factors Bmi-1, c-myc, and Snail, and the basal-like cytokeratin 
CK5.
In addition the four established biomarkers used in clinical prognostication, 
estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor 
receptor-2 (HER2), and the proliferation marker Ki67, were studied by IHC. HER2 
gene	amplification	was	further	confirmed	by	chromogenic	 in situ hybridization 
(CISH), if the IHC result was positive (2+ or 3+). 
For	analysing	the	subtype	approximations	to	the	subtypes	defined	by	genetic	
array testing, the tumors were divided to seven subtypes by using IHC: luminal 
A (ERorPR+HER2-), luminal B (ERorPR+HER2+), HER2 overexpressing (ER-
PR-HER2+), triple negative (ER-PR-HER2-), basal-like (ER-PR-HER2-CK5+), 
unclassified	(ER-PR-HER2-CK5-)	and	luminobasal	(ERorPR+CK5+).	
All statistical analyses were performed using SPSS 13.0 for Windows (SPSS 
Inc., Chicago, ILL, USA).
RESULTS AND CONCLUSION
The proteins studied were divided into three categories according to their relation 
to tumor dormancy. 
The expression of ER, STC-1, STC-2, Bcl-2, and Bmi-1 was associated with late 
relapse. The proteins associated with early tumor progression were: HER2, Ki67, 
p53, Maspin and CK5. The presence of PR, c-myc, and Snail did not correlate with 
the time of tumor recurrence.
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INTRODUCTION
Regardless of the vast progress made in the diagnosis and treatment of breast 
cancer, distant metastases remain the main cause of breast cancer-related deaths. 
Even early detected breast cancers, with no detectable metastases, have the potential 
risk to recur later, years after the primary treatment. Breast cancer can remain 
dormant, not progressing for a long period of time and, for reasons not understood, 
can reactivate as a local relapse or distant metastasis. At present, the clinical data, 
the histopathological parameters, tumor size, histological type, grade, and axillary 
lymph node status, together with the classical biomarkers, ER, PR, HER2,  and 
Ki67, determined from the primary tumors, are the main factors which constitute 
the guidelines for treating breast cancer patients. These parameters are powerful in 
predicting the time of cancer recurrence, but they do not give us tools for dealing 
with the dormant residual cancer cells. 
Breast cancer is composed of a population of cells which are heterogenous in 
their	molecular,	genetic,	and	protein	expression	profiles,	and	so	are	the	disseminated	
tumor cells (DTC) which escaped from the primary tumor. The heterogenous nature 
of the DTCs and the poorly understood mechanisms, which either keep these cells 
in a quiescuent state or awake them from dormancy are the main reasons why we 
can	not	therapeutically	influence	tumor	dormancy	and	inhibit	the	cancer	recurrence.	
This hampers the formulation of a tailored therapy. 
The research on tumor dormancy has been mostly based on cell culturing and 
animal models, with focus on angiogenesis, immunology and cancer stem cell theory. 
The aim of investigations on tumor dormancy is to identify new biomarkers, i.e 
markers of tumor dormancy that would better predict the outcome of breast cancer 
patients and help to develop new therapeutic strategies.
In addition, there have been efforts to identify markers circulating in the blood 
of breast cancer patients in the remissive phase, which could be used for predicting 
an upcoming relapse. To be useful, such markers should be capable of foretelling 
whether the tumor is still dormant, or activated and starting to progress. If such 
markers were available, it could be possible to begin treatment already before 
metastatic dissemination of the tumor. 
12
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REVIEW OF THE LITERATURE
1. THE EPIDEMIOLOGY OF BREAST CANCER 
INCIDENCE
Breast cancer is the most common cancer in Finland among women. Altogether, 
4674 new breast cancers were diagnosed in Finland in 2010. The number of new 
breast cancer cases has steadily risen from 1953 to 2007 (Fig. 1). The annual number 
of breast cancer cases is predicted to rise from 4090 in the period 2005–2007 to 
5119 in 2020, an increase of 25%.  
The	age-specific	and	age-adjusted	incidence	rate	of	breast	cancer	 in	Finland	
in	2006-2010	in	all	ages	was	90.2	(www.finnishcancerregistry.fi)	(Table	1).	The	
incidence was highest in patients in the age category of 60-64 years, by 391.4 per 
100,000. The youngest breast cancer patient in this time period was 15 years old. 
The highest rates concentrate to the menopausal and postmenopausal ages between 
the incidences 290.7 (50–54 years) and 389.8 (65–69 years) (Table 1).
Fig. 1 Annual numbers of cases 
of selected cancers in 
Finland in 1953–2007, 
and prediction until 2020, 
females, Finnish Cancer 
Registry 2010
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Table 1. Age-specific and age-adjusted incidence rates of female breast cancer in 2006–2010 per 
100,000, Finland, Finnish Cancer Registry 2010
Age range 
(years) 15-25 30-39 40-49 50-54 55-59 60-64 65-69 70-84
all 
ages
Incidence 2.5 33.5 247.6 290.7 319.1 391.4 389.8 310.8 90.2
MORTALITY
The leading fatal cancer among women in Finland is breast cancer (Fig. 2). The 
number of breast cancer deaths in 2010 was 887, which comprises 16% of all 5543 
female cancer deaths (mortality 14.7/100,000). The second highest cause of female 
cancer death is lung cancer, which is predicted to equal the mortality of breast 
cancer in 2020 (Fig. 2).
The annual number of cancer deaths in 2020 is predicted to increase by 13% 
in females and by 18% in males, compared with the recorded annual numbers of 
cancer deaths in 2005–2007. Breast cancer mortality has decreased slightly in the 
past few years, and the mortality has been estimated to decrease to the level of 
female lung cancer mortality by 2020 (Fig. 2).
The annual number of breast cancer deaths in females is predicted to rise from 
846	in	2005–2007	to	894	in	2020	(+	6%)	and	the	age-adjusted	rate/100,000	is	
predicted to decline from 14.8 in 2005–2007 to 11.3 in 2020 (-24%). 
Fig. 2 Age-adjusted mortality 
from selected cancers 
in Finland in 1953–2007, 
and prediction until 2020, 
females. Finnish Cancer 
Registry 2010
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SURVIVAL
The 5-year relative survival of breast cancer patients in Finland was 89% among 
patients diagnosed between 2002–2009, and newly observed in 2007–2009 
(Finnish Cancer Registry 2010), Table 2.
Table 2. 1-year and 5-year relative survival ratios (%) of Finnish female cancer patients diagnosed in 
2002–2009 and observed in 2007–2009 in the most frequent primary site, Finnish Cancer 
Registry 2010.
Primary site 1 year 5 years
All sites 79 65
Breast 97 89
Pancreas 19 3
Colon 78 61
Ovary 80 49
Non-Hodgkin’s lymphoma 77 64
Stomach 48 25
Corpus uteri 93 82
Brain, central nervous system 78 69
Liver 18 3
Rectum, rectosigmoid, anus 84 65
The relative survival of women with breast cancer increased greatly from 1964 to 
2003	in	all	five	Nordic	countries.	The	breast	cancer	incidence	increased	rapidly,	but	
mortality nevertheless remained largely unchanged. The progress in 5-year relative 
survival was around 20 to 30%, and the greatest improvement was in Finland. 
The 10-year survival for breast cancer in the Nordic countries was highest during 
1999–2003, with the highest rate in Finland, N: 172888, RS: 77% (CI  76–79) 
(Tryggvadottir et al. 2010).
The future scenario for breast cancer patients seems to be the following: there 
are consistently more women who live with primary and relapsed, treated breast 
cancers, and whose disease has taken a more chronic course. In Finland the number 
of	prevalent	breast	cancers	on	January	the	first	2011	was	57,000	(Finnish	Cancer	
Registry 2010).
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2. ETIOLOGY OF BREAST CANCER
RISK FACTORS
Endogenous estrogen
Epidemiologic studies have shown that many risk factors increasing the probability 
of developing breast cancer are associated with life-long exposure to endogenous 
estrogen. Breast cancer occurs more frequently among women who have early 
menarche,	who	remain	childless,	or	have	only	a	few	children,	and	the	first	delivery	
at a later age. Infertility, lack of breast feeding and a late age at menopause also 
increase the risk (Kesley et al. 1993). A lower risk for breast cancer has been reported 
in women who have had an early full-term pregnancy (Macmahon et al. 1970, 
Russo and Russo 1982). The protective effect of lactation appears to be limited 
to long-term cumulative breast feeding, preferably exceeding two years (Chang-
Claude et al. 2000).
Kotsopoulos et al.  analysed 4,655 ductal and 659 lobular cases of postmenopausal 
breast cancers from the Nurses Health Study (NHS) initiated in 1976 (Kotsopoulos et 
al.	2010).	They	found	that	the	age	at	menarche,	age	at	first	birth,	and	postmenopausal	
hormone use was more strongly associated with lobular cancers than ductal cancers. 
These epidemiological analyses demonstrate that different types of breast cancer 
differ in their association with a number of risk factors, and indicate that breast 
cancers are heterogeneous diseases and may have different etiologies. 
Exogenous hormones
The evidence points to a small increase in the relative risk associated with the use 
of combined oral contraceptives, especially among current and recent users. This is 
not related to the duration of use, or the type or dose of the preparation, and may 
partly be due to detection bias (IARC 1999). 
Hormone replacement therapy (HRT) is linked to an increased risk of breast 
cancer according to the report from the Women’s Health Initiative (Narod 2011). The 
risk of breast cancer increases after therapies with both estrogen and progesterone, 
when compared to estrogen alone. After cessation of HRT, the increased risk 
dissipates within two years. Factors associated with an increased risk of breast 
cancer include the initiation of hormone use immediately after menopause, a lean 
body mass, and high mammographic breast density (Narod 2011).
16
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Familial risk of breast cancer
Familial risk for breast cancer has been known for over 100 years (Broca 1866). A 
review of 74 published studies (Pharoah et al. 1997) calculated a relative familial 
risk	of	2.1	(95%	CI	2.0	-	2.2)	for	breast	cancer	in	any	first	degree	relative,	2.3	for	a	
sister affected, and 2.0 for an affected mother, and a relative risk of 3.6 if both an 
individual’s mother and a sister were affected.  The most important genes related 
to familial breast cancer are BRCA1 and BRCA2, which explain about 20% of the 
overall familial risk of breast cancer with a higher risk at younger ages (Antoniou 
et al. 2001). 
Nutrition
The report of the World Cancer Research Fund (WCRF 2007) has clearly established 
that overweight/obesity is a risk factor for developing breast cancer. Gaining weight 
during	aging	was	associated	with	a	statistically	significant	increase	in	the	risk	of	
breast cancer among both pre- and postmenopausal women (Cummings et al.2009).
A strong positive association with height was found among Norwegian women 
who were born during World War II. The study showed that early nutrition, during 
the  period of gestation, may play a role in the etiology of breast cancer. (Nilsen 
et Vatten 2001).
To	date,	there	is	very	limited	information	on	the	potential	role	of	a	specific	dietary	
pattern in breast cancer survival (Hauner and Hauner 2010). Several prospective 
studies on fruit and vegetable consumption as well as on the intake of vitamins, 
minerals,	and	trace	elements,	have	not	revealed	any	significant	association	with	
breast cancer (Cummings 2009, WCRF 2007), and normal body weight is the only 
demonstrated protective factor to avoid breast cancer (Cummings et al. 2009).
Smoking and alcohol
In a study by Xue et al. (2011), breast cancer incidence was higher among current 
and past smokers, among those who had started smoking at a younger age, and those 
with a longer duration of smoking and more pack-years of smoking. Active smoking 
was associated with an increased risk of breast cancer among postmenopausal 
women. An association between passive smoking and an increased risk of breast 
cancer has also been suggested (Luo et al. 2011). 
The most recent statistics on alcohol consumption and the risk of breast 
cancer were published in November 2011. Breslow et al. studied prospectively 
the association between the quantity and frequency of alcohol consumtion and 
cancer-specific	mortality	using	the	data	of	the	National	Health	Interview	Survey	
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(n=323,354). Women who drank more frequently tended to have an increased 
risk of breast cancer (Breslow et al. 2011). In the study of  Chen et al., 5.0–9.9 g of 
alcohol	intake	per	day,	equivalent	to	3–6	drinks	per	week,	significantly	increased	
the risk of breast cancer (Chen et al. 2011). 
Physical activity
The association between physical activity and reduced risk of breast cancer is 
independent of menopausal status. Among the most physically active women, the 
risk decreased by about 20–40%. Activity that is sustained throughout life, may 
be	particularly	beneficial	(IARC	2002).
In their study, Zeng et al. determined the effect of physical activity on DNA 
methylation and predicted the consequence of this effect on gene expression and 
breast cancer survival. Their results suggested that increasing physical activity after a 
breast cancer diagnosis may affect epigenetic regulation of tumor suppressor genes, 
which has a favorable impact on the survival outcome of breast cancer patients 
(Zeng et al. 2011).
18
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3. THE ORIGIN OF BREAST CANCER
Breast carcinoma is a malignant epithelial tumor characterized by the invasion of 
adjacent	tissues	and	the	ability	to	metastasize	to	distant	sites.	The	vast	majority	of	
these tumors are adenocarcinomas believed to derive from the mammary gland 
parenchymal epithelium, particularly from cells in the terminal duct lobular units 
(TDLU, Fig 3), (Wellings et al. 1975).  The hypothesis of ductal origin (Gallagher 
et Martin 1969, Levin et al. 1964, Sandison 1962) is based on the presence of 
preneoplastic epithelial hyperplasia in ducts. Sandison studied the histopathology 
of breasts in 800 autopsies, and found that the epithelial proliferations, both ductal 
and ‘acinar’ were more extensive in cancer breasts than in non-malignant breasts 
(Sandison 1962).
The human breast undergoes a complex series of changes from embryonic life 
to senescence. The developmental phase begins at puberty and includes the early 
stages of morphogenesis, from the formation of the nipple epithelium to lobule 
formation. Glandular development begins with growth and division of small bundles 
Fig. 3 TDLU
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of primary and secondary ducts, forming bulbous terminal end buds (TEB), which 
then progress to alveolar buds (Abs) that are smaller ductless structures clustered 
around the duct, forming a Type 1 lobule, also called TDLU, (Russo et al. 1990). 
Further gradual maturation from Type 1 lobules is a gradual process of sprouting 
of new Abs, called ductules. The full maturation of the breast ductules is attained 
during pregnancy and lactation, differentiating in this phase into ductules called 
alveoli and acini. 
The mammary duct is composed of two layers of epithelial cells, the inner luminal 
epithelial and the outer myoepithelial compartment, and a basement membrane 
between	the	myoepithelial	 layer	and	the	surrounding	stroma	(Gudjonsson	et al. 
2005).
Gudjonsson	et al. have previously shown that a subset of the luminal epithelial 
cells could convert into myoepithelial cells in culture, signifying the possible 
existence of a progenitor cell. Later, they succeeded in identifying and isolating 
the putative precursor in the luminal epithelial compartment. By using cell surface 
markers and immunomagnetic sorting, they isolated two luminal epithelial cell 
populations	from	primary	cultures	of	reduction	mammoplasties	(Gudjonsson	et al. 
2002). In clonal cultures, only the minor suprabasal derived epithelial cells were 
able	to	generate	themselves	as	well	as	the	major	epithelial	cells	and	myoepithelial	
cells, thus expressing stem cell properties with the ability to form entire TDLUs 
inside 3-D reconstituted basement membrane  (Bartek et al.	1985,	Gudjonsson	et 
al.	2002).	The	first	identification	of	cancer	stem	cells	(CSCs)	in	solid	tumors	was	
demonstrated	in	breast	cancer	by	Al-Hajj	and	colleagues	 in	2003.	 	They	used	a	
model in which human breast cancer cells were grown in immunocompromised 
mice and were able to distinguish the tumor initiating from the nontumorigenic 
cancer	cells	based	on	cell	surface	marker	expression		(Al-Hajj	et al. 2003). 
GENE ALTERATIONS IN BREAST CANCER
Breast cancer is a genetically heterogeneous disease. As in malignancies in other 
anatomical organs, the development of breast cancer is a consequence of the 
accumulation of sequential genetic alterations, including activation of oncogenes 
(e.g.	by	gene	amplification),	such	as	 the	epidermal	growth	 factor	EGFR, MYC, 
HER2 and Cyclin D1 or inactivation tumor suppressor genes, such as TP53, the 
retinoblastoma gene RB1, the insulin-like growth factor II coding gene IGF2R and 
CDH1 coding E-cadherin. (Ellis et al. 2003,b). 
The variability in the gene expression of tumors can be measured by using 
microarray	 technology	which	 quantifies	 the	 expression	 levels	 of	 thousands	 of	
genes (Perou et al. 2000). Despite the great variation in gene expression, there are 
20
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also striking similarities between tumors, providing new opportunities for tumor 
classification.	
Metastatic activity presents the endpoint in a sequence of genomic changes 
underlying the progression of the epithelial cells into invasive tumor cells which 
cause a lethal disease. Metastases in general contain more genomic alterations than 
do their corresponding primary tumors (Hampl et al. 1999).
4. MORPHOLOGICAL CLASSIFICATION OF BREAST CANCER
INVASIVE BREAST CANCERS
The	latest	version	of	breast	cancer	classification	dates	from	the	year	2003	(Ellis	et 
al.  2003,a). There are 19 histologically different subtypes of breast cancer. Invasive 
ductal carcinoma (Fig. 4 a, b,c) is the most frequent subtype, comprising 40–75% 
of all breast cancers. The next most common type is lobular carcinoma (Fig. 4 d) 
which represents 5–10% of breast cancers. The proportion of lobular carcinoma 
has increased during the past 20 years, probably due to HRT. Lobular carcinoma 
is found approximately 1–3 years later than ductal carcinoma (Li et al. 2000). The 
outcome of these usual types is often worse than that of the more rare subtypes. 
The	histopathological	grading	is	 influenced	by	the	amount	of	 tubule	formation,	
nuclear atypia and mitotic count (Elston and Ellis 1991). 
NON-INVASIVE IN SITU CANCERS
The stage in malignant breast tumor development, at which the ductal luminal 
malignant epithelium does not yet invade through the basement membrane into 
the surrounding stroma, is called ductal carcinoma in situ	(DCIS).	DCIS	was	first	
recognized by Bloodgood in 1893 (Bloodgood 1934), and DCIS has been shown to 
arise within the TDLUs of the breast (Wellings et al. 1975). 
DCIS	is	classified	into	three	groups,	i.e.,	 low	grade	DCIS,	intermediate	grade	
DCIS, and high grade DCIS. The grading of DCIS is based on nuclear atypia, the 
polarity of cells and necrosis (Tavassoli et. al 2003a, Elston and Ellis 1998). The 
risk of  DCIS to develop into invasive breast cancer has been estimated as 8–10-
fold, compared to the risk for a reference population (Fitzgibbons et al. 2000).
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Fig. 4 Ductal carcinoma grade 1 (a), Ductal carcinoma grade 2 (b), Ductal carcinoma grade 3 (c), 
Lobular carcinoma (d)
a b
c d
LOBULAR NEOPLASIA 
The histological features and the term lobular carcinoma in situ (LCIS) were 
characterized and assigned by Foote and Stewart in 1941 (Tavassoli et al. 2003b, 
Foote and Stewart 1941). The term lobular neoplasia (LN) includes the full spectrum 
of proliferation of the characteristic cell type within acini, ranging from atypical 
lobular hyperplasia (ALH) to LCIS. LN constitutes a risk factor and a non-obligatory 
precursor for the development of invasive breast cancer of either ductal or lobular 
type (Tavassoli et al. 2003b). The relative risk for subsequent development of 
invasive carcinoma among patients with LN ranges from 6.9 to about 12 times of 
that expected in women without LN (Anderson 1974).
22
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5. PROGNOSTIC AND PREDICTIVE FACTORS
CLINICOPATHOLOGICAL PARAMETERS
Classical clinicopathological parameters guide the treatment of patients after initial 
surgery (Goldhirsch et al. 2009, Goldhirsch et al. 2011). In addition to clinical 
features, like age and menopausal status, the type of therapy is based on pathological 
reports derived from histological analysis of primary breast cancer samples, and 
include	definition	of	 tumor	size,	axillary	 lymph	node	status,	histological	grade,	
tumor type and lymphovascular invasion. 
TRADITIONAL PROGNOSTIC AND PREDICTIVE BIOMARKERS ER, PR, HER2, KI67
Breast cancer treatment has undergone several changes in the past decades due 
to	the	discovery	of	specific	predictive	biomarkers	that	define	different	molecular	
subgroups of tumors that allow more individualized therapies. For over 30 years, 
the established molecular biomarkers, such as ER and PR, have been used to 
treat	patients	benefiting	from	endocrine	therapy	(Jordan	1993).	HER2	has	been	
validated not only as a prognostic factor, but also as a predictor of response to anti-
HER2 therapy. The proliferation marker Ki67 has been used for over 10 years as a 
prognostic marker, and has recently emerged as an important marker having several 
applications	in	adjuvant	and	neoadjuvant	therapy	(Weigel	and	Dowsett	2010).
ER
The role of estrogen as the most important growth factor of breast cancer was 
first	demonstrated	by	Beatson	1896,	when	regression	of	a	metastatic	tumor	was	
induced	by	ovariectomy	(Beatson	1896).	ERs	were	first	 identified	by	Elwood	V.	
Jensen in 1958 (Jensen and Jordan 2003). The gene for a second estrogen (ERbeta) 
was	identified	in	1996	by	Kuiper	et	al.	 (1996).	ERbeta	and	ERalpha	share	high	
sequence identity (Katzenellenbogen 1980), especially in the regions or domains 
responsible	 for	specific	binding	 to	DNA	and	 ligands	 (Kuiper	et al. 1996).  The 
current determination of ER positivity in breast cancer samples is based on IHC 
labeling of ERalfa.
Approximately	75%	of	breast	cancers	are	ER-positive	(Nadji	et al. 2005). ER and 
PR belong to the steroid hormone receptor superfamily, including receptors for the 
steroid, retinoid, and thyroid hormones (Carcon-Jurica et al. 1990, Evans 1988). In 
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the classical estrogen-dependent pathway, estradiol (E2) binds ERalpha, and the 
resulting complex translocates into the nucleus, binds to estrogen response elements 
(ERE), resulting in the transcription of genes that promote cellular proliferation, 
for example those coding for cyclin-dependent kinases (CDK). Also non-genomic 
(i.e., not involving ERalpha-induced transcription) pathways of estrogen action have 
been described. E2 can stimulate phosphorylation of the adapter protein Shc and 
its interaction with ERalpha (Russo 2004; Tsai and O´Malley 1994). 
Although 67% of breast cancers manifest during the postmenopausal period, 
the	vast	majority,	95%,	are	 initially	hormone-dependent	(Hu	et al. 2001). This 
indicates that estrogens play a crucial role in breast cancer development. However, 
it is still unclear whether estrogens are truly carcinogenic in breast tissue. Most of 
the current understanding of the carcinogenicity of estrogens is based on studies 
on experimental animals and on clinical observations (Hu et al. 2001). 
Several studies have shown that the apparent effect of ER status on prognosis is 
limited to the early follow-up period (Lundin et al. 2006, Raemaerkers et al. 1985, 
Andry et al. 1989, Shek and Godolphin 1989, Crowe et al. 1991).
ER-positive tumors are more frequent among postmenopausal women than 
among younger women. Compared to patients with an ER-negative status, those 
with ER-positive tumors have a more indolent disease tending to display later 
recurrences, tumor dormancy, and a higher rate of bone metastases (Hess et al. 
2003). The cellular and molecular mechanisms behind this distinct biological 
behavior are not known.
An estrogen receptor-positive status in breast cancer is associated with a positive 
response to hormonal therapy, a favorable prognosis, and a long disease-free 
life and overall survival (Vollenweider-Zerargui et al. 1986). Unfortunately, the 
correlation between an ER-positive status and endocrine dependence is not perfect. 
Approximately 40% of ER-positive tumors do not respond to endocrine therapy 
(Clark  et al. 1983, Horwitz et al. 1975), suggesting that certain ER+ tumors do not 
regress with endocrine treatment due to a defect in the estrogen response pathway, 
distal to the binding step to EREs, thus leading to autonomous growth. Based on 
the	finding	that	PR	is	induced	by	estrogen	in	normal	reproductive	tissues	and	in	
human breast cancer cells in culture, Horwitz et al. hypothesized that PR might 
be a better marker than ER for an intact estrogen pathway (Horwitz et al. 1975). 
ER-positive breast cancer has the unfortunate propensity of recurring even after 
decades	of	remission.	The	 long-term	outcome	for	these	patients	 is	significantly	
worse than for patients with ER-negative tumors, regardless of menopausal status 
(Brewster et al. 2008). 
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PR
Approximately	55%	of	breast	cancers	are	PR-positive	(Nadji	et al. 2005). Tumors 
expressing PR but not ER are uncommon, and represent  < 1–1.5 % of all breast 
cancers	(Viale	et	al.	2007,	www.finnprog.fi).	PR	is	also	a	member	of	the	steroid/
thyroid hormone nuclear receptor superfamily. It has two isoforms, PRalpha and 
PRbeta, which function as ligand-dependent nuclear transcription factors. 
The prognostic and predictive value of PR expression has remained controversial. 
The results of randomized clinical trials in early breast cancer have shown that PR 
may add to the potency of ER for predicting the response to endocrine therapy 
in metastatic breast cancer (Early Breast Cancer Trialists 1998, 2005). Although 
ER and PR are members of different steroid hormone receptor subfamilies, there 
is evidence of crosstalk between ER and PR signalling pathways. In many cases, 
progestins suppress the stimulatory effects of estrogens in target cells. Estrogen 
has been shown to increase the expression of PR mRNA in uterine cells, and 
progestins suppress the stimulatory effects of estrogens in target cells. The molecular 
mechanisms underlying the antagonism of progestin on estrogen action are believed 
to be mediated via PR, but it is not known whether the ER protein or some other 
component of the ER signalling pathway is the target of repression (Kraus et al. 
1995). 
Liu et al. (2010) examined the value of PR for prognosis and the response to 
tamoxifen in a population-based series of 4,046 women with invasive early-stage 
breast cancer. Survival analyses for both the whole cohort and the ER-positive cases 
that were given tamoxifen therapy showed that patients with PR-positive tumors 
had	better	cancer-specific	survival	than	PR-negative	patients	(Liu	et al. 2010). 
Cui et al. demonstrated that IGF-I (insulin-like growth factor-1) inhibits 
progesterone receptor expression in breast cancer cells via the phosphatidylinositol 
3-kinase/akt/mammalian target of rapamycin pathway (Cui et al. 2003). Based 
on this observation, they suggested that low PR expression may indicate activated 
growth factor signalling in breast cancer cells, and therefore show an aggressive 
tumor	phenotype	and	resistance	to	hormonal	therapy.	PR	expression	may	define	
a subpopulation of breast cancer patients with a stronger dependence on hormone 
receptor-associated growth, and therefore a superior response to hormone therapy 
(Cui et al. 2005). 
HER2
The epidermal growth factor (EGF) was discovered by Stanley Cohen and Rita 
Levi-Montalcini in the early 1970s. After grinding up submaxillary glands and 
applying the extract to the eyelids of newborn mice, the eyelids of the mice opened 
earlier than normally (Sliwkowski 2003). This work led to the discovery, not only of 
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epidermal growth factor (EGF), but also of its prototypical receptor tyrosine kinase, 
epidermal growth factor receptor (EGFR). The discovery of EGF by Stanley Cohen 
from Vanderbilt University led to the Nobel Prize in Physiology and Medicine in 
1986. It was patented for cosmetic use by Greg Brown in 1989.
The Her2/neu gene (c-erb-B2) is a component of a four-member family of 
closely related growth factor receptors with tyrosine kinase activity, including 
epidermal growth factor receptors (EGFR or HER-1 (erb-B1), HER-2 (erb-B2), 
HER-3 (erb-B3), and HER-4 (erb-B4). 
HER2,	a	new	member	of	the	tyrosine	kinase	gene	family,	was	first	described	by	
King et al. (King et al.1985). The gene erb-B2	was	amplified	in	human	mammary	
carcinoma and it encodes HER2, an integral plasma-membrane receptor tyrosine 
kinase that is normally involved in signal transduction pathways, leading to cell 
growth and differentiation. 
Amplification	of	 the	(c-erB2) HER2 gene and RNA/protein over-expression 
correlate strongly (Pegram et al.	2000).	Amplification	of	the	HER-2/neu gene or 
over-expression	of	the	HER2	protein	has	been	identified	in	10	to	34%	of	breast	
cancers, and HER2 over-expression is usually associated with an aggressive tumor 
phenotype and poor outcome (Ross and Fletcher 1998, Slamon et al. 1987). This 
group	of	patients	benefits	significantly	from	anti-HER2	therapies.	In	addition	to	
the	Herceptin	treatment	of	patients	with	metastatic	disease,	adjuvant	treatment	
of primary, HER2- positive breast cancers with trastuzumab has been shown to 
markedly improve the patient’s outcome (Joensuu et al. 2009).
Ki67
Ki67	is	a	marker	of	cell	proliferation	first	identified	by	Gerdes	et.al. (1983), after 
immunization of mice with Hodgkin’s lymphoma cells.  Ki67 is a nuclear non-
histone protein; it was named after the researcher’s university. In this context, 
Ki stands for the Univercity of Kiel, Germany, and 67 refers to the number of the 
clone in the 96-well plate. 
Ki67 expression varies during the cell cycle. Ki67 is expressed during G1, S, 
G2 phases and mitosis, but not during the resting phase G0 (Gerdes et al. 1984). 
Numerous studies have shown that Ki67 has prognostic value for many types of 
malignant tumors. In breast cancer, a strong correlation has been found between the 
proportion of cells positive for Ki67, nuclear grade, age, and mitotic rate (Sahin et 
al.1991, Keshgegian and Cnaan 1995). The advent of new genetic tests has emphasized 
the role of proliferative genes, including Ki67, as prognostic and predictive markers. 
There	are,	however,	major	financial	issues	that	limit	the	use	of	multigene	tests	in	daily	
practice. In addition to being more economical, immunohistochemical staining for 
Ki67 can be done in parallel with other immunohistochemical markers, and it can 
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be included in the initial pathology report of the core biopsy or surgical specimen 
(Yerushalmi et al. 2010).
Cheang et al. (2009) described an immunopanel of ER, PR, HER2, and Ki67 
that can discriminate the hormone receptor-positive luminal A and B subtypes with 
an	accuracy	similar	to	that	of	a	50-gene	expression	profile.	Luminal	breast	cancers	
in which at least 14% of all cells are Ki67-positive were assigned to the luminal B 
category with a worse prognosis. Both cancer recurrence and death were more 
common in patients having tumors with Ki67 positivity above 14% (Cheang et al. 
2009, Yerushalmi et al. 2010). 
GENE EXPRESSION PROFILING  
Intrinsic breast cancer subtypes
Perou et al. (2000) showed that morphologically similar breast cancers can be 
divided into several groups, with different outcomes, based on their gene expression 
profiles.	These	studies	revealed	the	existence	of	molecularly	distinct	neoplastic	
disorders which appear to originate from different cell types. Four molecular classes 
of	breast	cancer	were	distinguished	with	their	‘intrinsic’	classification:	luminal	A	
and B cancers, HER2-positive and basal-like cancers. Luminal cancers were almost 
all ER-positive, and they expressed typically cytokeratin (CK) 8 and 18. Luminal 
A tumors were histologically mostly low-grade, and luminal B represented high-
grade tumors with a worse prognosis. The HER2-positive subtype of cancers that 
showed	over-expression	of	HER2	protein	and	amplification	of	the	HER2 gene did 
not express hormone receptors, and had a poor prognosis. The basal-like breast 
cancers overlapped markedly with ER-, PR-, and HER2-negative (triple negative) 
tumors. They had a poor prognosis and expressed cytokeratins of the basal epithelial 
layer, CK 5/6 and CK17 (Sorlie et al. 2001, Sorlie et al 2003, Sotiriou et al. 2003).
Surrogate definitions of the intrincic subtypes by IHC 
Gene	expression	profiling	is	not	used	in	clinical	practice	to	classify	tumors	because	
the	methods	are	expensive,	and	there	are	no	public	algorithms	available	to	define	
tumor	classification	based	on	gene	expression	profiling	(Koscielny	2010).	Instead	
of	using	gene	expression	profiles,	clinicians	use	surrogates	of	the	genetically	defined	
subtypes. They divide the tumors into different subgroups, using IHC staining 
with	specific	antibodies	to	the	hormone	receptors,	HER2,	EGFR,	and	the	basal	
cytokeratins.
27
The mRNA-based, 21-gene Genome Health Recurrence Score (GHI-RS) has been 
shown to be highly reproducible. It has become widely used in the United States, 
but not in many other countries due to its high cost. Cuzick et al. (2011) studied 
how much of the information of GHI-RS can be gained with the standard IHC 
markers ER, PR, Ki67, and HER2. They suggested that the amount of prognostic 
information obtained by these four widely used IHC assays is compatible to that 
obtained with the GHI-RS, and represents an inexpensive prognostic test battery for 
identifying	women	with	a	low	risk	of	recurrence,	who	would	therefore	not	benefit	
additionally from further chemotherapy. 
The 12th St Gallen International Breast Cancer Conference (2011) Expert Panel 
adopted a new approach to classifying patients for therapeutic purposes. It is 
based on the recognition of intrinsic biological subtypes within the breast cancer 
spectrum. For practical purposes, the IHC surrogates to the intrinsic subtypes were 
defined	as	 follows:	 luminal	A=	ERorPR+HER2-,	 luminal	B=	ERorPR+HER2+,	
HER2 overexpressing (ER-PR-HER2+), triple-negative (basal-like)=ER-PR-HER2- 
(Goldhirsch et al. 2011).	A	modified	subtype	definition	was	used	by	Cheang	et al. 
and Carey et al. who further distinguished the triple negative basal-like phenotype 
subtype	by	EFGR	and	CK5	to	a	more	specific	definition	of	basal-like	breast	cancer	
which	better	predicts	breast	cancer	survival.	They	defined	the	basal-like	=	ER-
PR-HER2-CK5+	and	unclassified=	ER-PR-HER2-CK5-	IHC	subtypes	(Cheang	et 
al. 2008, Carey et al. 2006). Including EGFR and CK5 as positive IHC markers, 
has previously been shown to accurately identify basal-like tumors from gene 
microarray	data	with	100%	specificity	and	76%	sensitivity	(Nielsen	et al. 2004). 
Later, a new entity between basal and luminal breast cancer, the basoluminal subtype 
(ERorPR+CK5+)	was	identified	(Laakso	et al. 2006).
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6. METASTATIC DISSEMINATION
The understanding of events in the metastatic cascade of tumors is essential for 
finding	factors	that	regulate	the	balance	between	tumor	dormancy	and	escape	from	
the dormant state (onset of metastases) (Pantel et al. 2009). Distant metastatic 
cascades of solid epithelial tumors are formed when individual cancer cells detach 
and	lose	their	adhesion	to	adjacent	cells	in	the	primary	tumors,	and	disseminate	
via hematogenous or lymphatic routes as circulating tumor cells (CTC). They begin 
to grow and form one or more recurrent/metastatic tumors, at distant sites and 
organs from the primary tumor.
The malignant metastatic capability of tumors must be an inherent propensity 
compared to benign neoplasms and, for example, basaliomas, which have the 
capacity to invade but not to metastasize. It is currently believed that the metastatic 
property is achieved at an early state of cancer development, and those DTCs and 
CTCs which have achieved this genetic stage possess this capability.
Solid epihelial tumors differ in their patterns to metastasize. For some tumor 
types, e.g. head and neck cancer, the correlation between lymph node metastases 
and distant metastases is strong. For breast cancer, this correlation is less evident. 
Approximately 20–30% of breast cancer patients who are free of axillary lymph 
node metastases develop distant metastases. So, breast tumor cells can bypass the 
lymph nodes and disseminate directly through the blood to distant organs. Gene 
expression	profiling	studies	have	shown	that	the	molecular	pathways	for	lymphatic	
dissemination	differ	from	the	hematogenous	pathway	(Wölfle	et al. 2003). In breast 
cancer patients, hematogenous dissemination seems to be a very early event in 
tumor progression, so the disseminated tumor cells (DTC) found in the bone marrow 
might represent ‘immature’ tumor cells, as they have a limited life span and usually 
do not proliferate. Nevertheless, the presence of these DTCs accurately predicts the 
development of distant metastases. Some of the disseminated tumor cells start to 
proliferate at the distant site and acquire genetic mutations independent of those 
in the primary tumor. Some factors contributing to metastasis formation are listed 
in Table 6 (sectio 8, page 39). 
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7. TREATMENT OF BREAST CANCER
TREATMENT OF EARLY BREAST CANCER
Early breast cancer means a state in breast cancer development in which the disease 
is detected only in the breast, or in the case of axillary node-positive women, the 
breast and locoregional lymph nodes, and the entire detected disease can be removed 
surgically. However, undetected deposits of disease may remain either locally or at 
distant sites and if untreated, could over the next 5, 10, 15, or more years develop into 
a	life-threatening	clinical	recurrence.	The	main	aim	of	systemic	adjuvant	treatment	
is to control any remaining deposits of disease, to reduce the recurrence rate.
The 11th St Gallen (Switzerland) Conference on the Primary Therapy of Early 
Breast Cancer in 2009 proposed a new treatment selection algorithm for the 
management of early breast cancer (Goldhirsh et al. 2009). The Consensus Meeting 
considered the aspects of local and regional treatments, including surgical margins, 
indication for sentinel node biopsy, and the role of prophylactic mastectomy. Re-
excision was considered mandatory if invasive cancer or DCIS is present at the 
inked surgical margin.
The Consensus listed the different criteria to clarify the therapeutic decision-
making	algorithm,	which	addresses	the	three	distinct	questions:	What	justifies	the	
use	of	endocrine	therapy?;	What	justifies	the	use	of	anti-HER2	therapy?	and;	What	
justifies	the	use	of	chemotherapy?	(Goldhirsch	et al. 2009, Table 3). 
Any	positive	level	of	ER	expression	is	considered	sufficient	to	justify	the	use	of	
endocrine	adjuvant	therapy	in	almost	all	patients.	Over-expression	or	amplification	
of HER2 by standard criteria is an indication for anti-HER2 therapy for all but the 
very lowest risk invasive tumors. 
The	threshold	for	using	cytotoxic	chemotherapy	is	the	most	difficult	one	to	define.	
Patients receiving anti-HER2 therapy conventionally also receive chemotherapy 
either preceding or concurrent with anti-HER2 treatment. Chemotherapy is the 
mainstay	of	the	adjuvant	therapy	of	patients	with	triple-negative	disease	who	are	
at	sufficient	risk	of	relapse	so	as	to	justify	its	utilization.
The threshold for recommending chemotherapy for patients with ER-positive, 
HER2-negative	disease	is	particularly	difficult	to	define.	These	patients	include	a	
spectrum ranging from those at low risk for whom there is little evidence supporting 
the addition of chemotherapy to endocrine therapy, to those with a high-risk disease 
and	 limited	ER	 expression,	 for	whom	 chemotherapy	 appears	 clearly	 justified.	
Chemoendocrine therapy guidelines in ER-positive HER2-negative disease are 
summarized in Table 4 (Goldhirsch et al. 2009).
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Table 3. Thresholds* for treatment modalities
Treatment modility Indication Comments
Endocrine therapy Any ER staining# ER-negative and PR-positive 
are probably artefactual 
(Ibrahim et al. 2008)
Anti-HER2 therapy ASCO/CAP HER2-positive 
(>30% intense and complete 
staining (IHC) or FISH>2.2+)#
May use clinical trial 
definitions
Chemotherapy in HER2-
positive disease  
(with anti-HER2 therapy)
Trial evidence for 
trastuzumab is limited to use 
with chemotherapy or after it 
Combined endocrine therapy 
+ anti-HER2 therapy without 
chemotherapy in strongly 
ER-positive, HER2-positive is 
logical but unproven
Chemotherapy in triple-
negative disease
Most patients#0 No proven alternative; most 
at elevated risk
Chemotherapy in ER-positive, 
HER2-negative disease  
(with endocrine therapy)
Variable according to risk# See Table 4
* Most factors are continuous, but a binary decision needs to be made at some level.
# Patients with tumors >1cm in size without axillary nodal involvement and without other features indicating 
increased metastatic potential (e.g. vascular invasion) might not need adjuvant systemic therapy. If the tumor 
is, however endocrine-responsive, endocrine therapy should be considered.
0 Medullary carcinoma, apocrine carcinoma, and adenoid cystic carcinoma do not require chemotherapy due to 
their low risk despite being triple negative (provided that, as is usually the case, they have no axillary node 
involvement and no other signs of increased metastatic risk).
ASCO, American Society of Clinical Oncology; CAP, College of American Pathologists
Goldhirsch et al 2009
Table 4. Chemoendocrine therapy in patients with ER-positive, HER2-negative disease
Relative indications 
for chemoendocrine 
therapy
Factors not useful for 
decision
Relative indications 
for endocrine therapy 
alone
Clinicopathological 
features ER and PR
Lower ER and  
PR level
Higher ER and  
PR level
Histopathological 
grade
Grade 3 Grade 2 Grade 1
Proliferation High* Intermediate* Low*
Nodes Node positive (4 or 
more involved nodes)
Node positive (1–3 
three involved nodes)
Node negative
PVI Presence of  
extensive PVI
Absence of  
extensive PVI
pT size >5 cm 2.1–5 cm <2 cm
Patient’s preference Use all available 
treatments
Avoid chemotherapy-
related side-effects
Multigen assays
Gene signature0
High score Intermediate score Low score
* Conventional measures of proliferation include assessment of Ki67-labelling index (e.g. low, <15%; intermediate, 
16–30%; high, >30%) and pathological description of the frequency of mitoses.
Goldhirsch et al 2009
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The 12th St Gallen International Breast Cancer Conference in 2011 adopted a 
new	approach	to	the	classification	of	patients	for	therapeutic	purposes	based	on	the	
recognition of intrinsic biological subtypes within the breast cancer spectrum. For 
practical purposes, the subtypes may be approximated using clinicopathological rather 
than gene expression array criteria. In general, systemic therapy recommendations 
follow	the	subtype	classification,	and	the	systemic	treatment	recommendations	for	
subtypes are shown in Table 5 (Goldhirsch et al. 2011).
The primary treatment of early breast cancer is based on surgery of the primary 
tumor and the surgical manipulation of the axilla. In the last decade the method of 
sentinel node biopsy has partly replaced the conventional evacuation of the axillary 
lymph nodes.
The Panel in the 2011 Consensus meeting expressed the view that the routine 
use of IHC to search for low-volume metastatic disease in sentinel nodes was not 
indicated, since metastases revealed only by IHC would not alter the management 
protocol. Furthermore, isolated tumor cells, and even metastases up to 2 mm 
(micrometastases) in a single sentinel node, were not considered to constitute an 
indication for axillary dissection, regardless of the type of breast surgery carried out. 
The Panel accepted the option of omitting axillary dissection of macrometastases 
Table 5. Systemic treatment recommendations for subtypes
Subtype Type of Therapy Note of therapy
Luminal A Endocrine therapy only Few require cytotoxins 
(e.g. high nodal status or other 
indicator of risk: see text).
Luminal B  
(HER2 negative)
Endocrine ± cytotoxic therapy Inclusion and type of cytotoxins 
may depend on level of 
endocrine receptor expression, 
perceived risk and patient’s 
preference.
Luminal B  
(HER2 positive)
Cytotoxic + anti-HER2 + 
endocrine therapy
No data are available to support 
the omission of cytotoxins in this 
group.
HER2 positive 
(nonluminal)
Cytotoxins + anti-HER2 Patients at very low risk 
(e.g. pT1a and node-negative) 
may be observed without 
systemic adjuvant treatment.
Triple negative (ductal) Cytotoxins
*Special histological 
types
A. Endocrine responsive Endocrine therapy
B. Endocrine 
nonresponsive
Cytotoxins Medullary and adenoid cystic 
carcinomas may not require any 
adjuvant (if node-negative).
* Special histologic types: Endocrine responsive (cribriform, tubular, and mucinous); Endocrine nonresponsive 
(apocrine, medullary, adenoid cystic and metaplastic).
Goldhirsch et al 2011
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in the context of lumpectomy and radiation therapy for patients with a clinically 
node-negative disease and 1–2 positive sentinel lymph nodes, as reported from 
ACOSOG trial Z0011 with a median follow-up of 6.3 years. This practice should 
not, however, be extended more generally, for instance to patients undergoing 
mastectomy,	 those	who	will	not	 receive	whole-breast	 tangential	field	radiation	
therapy, or those with involvement of more than two sentinel nodes, as well as 
patients	receiving	neoadjuvant	therapy	(Goldhirsch	et al. 2011).
TREATMENT OF ADVANCED BREAST CANCER
Overall, survival of patients with metastatic breast cancer (MBC) is slowly but 
steadily improving. Every year, the risk of death has decreased by 1–2% (Giordano 
et al. 2004). The greatest improvement is most probably related to the development 
and widespread availability of modern systemic therapies. A distinct subset of 
MBC	patients	who	are	most	likely	to	gain	substantial	benefit	from	an	intensified	
multidisciplinary therapeutic approach is represented by ‘oligometastatic’ disease, 
which is characterized by solitary or only few detectable metastatic lesions that are 
usually limited to a single organ (Pagani et al. 2010). This population of “potentially 
curable” Stage IV disease is estimated to be 1–10% of newly diagnosed MBC patients 
(Hanrahan et al. 2005).
In	contrast	to	early	stage	disease,	for	which	Level	1	evidence	exists	for	the	majority	
of treatment options, there are few recognized therapeutic standards for advanced 
breast cancer (ABC), particularly after 1st line treatment. The advances have been 
slow and the median overall survival for patients with MBC is still only 2–3 years, 
although the range is wide. For HER2-positive ABC the development of anti-HER2 
agents has effectively led to a substantial improvement in the survival of these 
patients.	However,	for	triple-negative	ABC	no	significant	improvement	in	survival	
has yet been achieved, and ER-positive ABC, the most common subtype, overall 
survival has remained stable since the early nineties (Foukakis et al. 2011).
There are several widely used international and national guidelines for early 
stage breast cancer. The situation in markedly different for ABC and particularly 
MBC, for which only national efforts have been made. Acknowledging the urgent 
need	for	international	concord	in	this	field,	the	European	School	of	Oncology	(ESO)	
created an ABC Task Force in 2005, aiming to develop international consensus 
guidelines for managing ABC which could be applied worldwide, and also to identify 
areas where research/clinical trials are urgently needed. This Task Force has held 
public and interactive sessions during three consecutive European Breast Cancer 
Conferences, followed by the publication of manuscripts reviewing the available data 
and issuing the Task Force’s recommendations on several issues. This work also led 
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to the establishment of the 1st International Consensus Guidelines Conference on 
ABC (ABC 1) held in November 2011. Cardoso et al. (2012) published the summary 
of the guidelines developed on ABC 1. 
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8. THE PHENOMENON OF TUMOR DORMANCY
BACKGROUND OF TUMOR DORMANCY
Cancer dormancy is considered to be a protracted stage in progression, during 
which tumors remain occult and asymptomatic for a prolonged period of time. 
Tumor dormancy can present one of the earliest stages in tumor development, as 
well as a stage in micrometastasis or minimal residual disease left after surgical 
removal and treatment of primary tumors. Tumor dormancy, therefore, can occur 
in primary as well as in secondary tumors (Udagawa 2008). The former type of 
dormancy can be called primary dormancy and the other metastatic dormancy 
(Klein 2011). Delayed recurrences are typical in breast cancer. 
The fact that dormant tumors are highly prevalent in the general population 
is of clinical importance (Harach et al.1985, Black and Welch 1993, Nielsen et 
al. 1987).  In addition, the dormant tumor cells remaining after primary tumor 
removal or treatment are commonly refractory to chemotherapy (Aguirre Chiso 
2007, Wikman et al. 2008). 
The progression of a malignant solid tumor capable of invading the surrounding 
stromal tissue and of disseminating, i.e. sending metastatic tumor cells from the 
primary tumor to distant organs, was earlier thought to have a continuous pattern. 
Several mathematical models for tumor growth have been developed, such as 
the exponential pattern of tumor growth, the continuous deceleration theory by 
Mayneord 1932, and the model of tumor cell proliferation by the Compertz equation. 
Compertzian growth kinetics, i.e. near-regular exponential growth at small cell 
numbers with decelerated growth at larger numbers, has been widely utilized for 
planning treatment regimens (Norton 1988). A continuous growth model, however, 
is not consistent with the results of several clinical studies.
	Continuous	growth	was	unable	to	explain	the	time	distribution	of	first-treatment	
failure in 1173 breast cancer patients undergoing mastectomy alone (Demiceli et 
al.	1996).	Indeed,	the	cause-specific	hazard	function	for	local-regional	recurrences	
and distant metastases displayed an early peak at approximately 18 months, a 
second peak at about 60 months, and then a tapered plateau-like tail extending 
up to 15 years.  
As an alternative to the continuous growth model, the tumor dormancy 
hypothesis was considered to provide a more reasonable description of tumor 
recurrence (Demiceli et al.	1997).	 	The	term	“dormancy”	dates	back	to	Hadfield	
(1954)	in	the	first	half	of	the	20th century, and was introduced by the pathologist 
Rubert A. Willis in his book “The spread of tumors in the human body”. The current 
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definition	of	tumor	dormancy	is	mainly	based	on	observations	and	hypotheses.	
Based	on	observations,	dormancy	has	been	defined	as	a	prolonged	latent	phase	(at	
least	5	years)	(Hadfield	1954)	that	occurs	between	primary	treatment	and	further	
disease progression.  It was assumed that the dormant tumor cells are in a state of 
temporary	mitotic	arrest	during	the	long	latent,	dormant	period	of	cancer	(Hadfield	
1954). It has been hypothesized that primary tumors shed tumor cells already at 
an early stage into the blood circulation (Butler and Gullino 1975, Fidler 1970). 
Today, tumor dormancy is simply understood as a stage in cancer progression in 
which residual disease is present, but not clinically apparent (Páez et al. 2011). The 
prevalence of clinical dormancy is unknown. When 20-year follow-up data from 
different periods in medical history are compared, the percentage of dormancy cases 
seems to have doubled in 40 years (Klein 2011, Joensuu and Toikkanen 1991). A 
clinical	dormancy	definition	would	thus	need	to	be	re-adjusted	to	actual	diagnostic	
and therapeutic procedures after decades of observation, and therefore would be 
always out-dated.
CLINICAL AND MOLECULAR MECHANISMS UNDERLYING TUMOR DORMANCY 
The	detection	of	dormant	tumor	cells	has	been	extremely	difficult	in	clinical	settings.	
Evidence of clinical tumor dormancy has been collected from autopsies of trauma 
victims (Harach et al. 1985, Nielsen et al. 1987), from clinical data on late recurrence 
or	relapse,	and	from	findings	of	disseminated	tumor	cells	(DTCs)	and	circulating	
tumor cells (CTC) in cancer patients, even years after the treatment of primary 
tumors. 
In recent years, extensive molecular and genetic characterization of DTCs and 
CTCs	has	 contributed	 significantly	 to	our	understanding	of	 the	 frequency	and	
prevalence of tumor dormancy (Riethdorf et al. 2008, Pantel et al. 2009).  Isolated 
tumor cells and micrometastases have been detected in the bone marrow of primary 
breast cancer patients (Wiedswang et al. 2003, Diel et al. 1996). Although patients 
with disseminated tumor cells have a higher risk of relapse, not all patients will 
develop recurrent disease (Janni et al. 2006).
Experimental studies have shown that early steps in hematogenous metastasis 
(intravasation,	survival,	arrest,	and	extravasation)	can	be	remarkably	efficient,	with	
greater than 80% of the cells successively completing the metastatic process to 
this point.
However, only a small subset of these cells (~ 2%, depending on the experimental 
model) can initiate growth as micrometastases, and an even smaller subset (~ 0.02%, 
depending on the experimental model) are able to persist and grow into macroscopic 
tumors (Allan et al.  2007). 
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The poorly understood mechanisms leading to growth activation and 
establishment of metastases have been intensively studied. Evidence shows that 
several different factors may contribute to growth activation, including the genetic 
predisposition of the dormant cells, as well as the immunological and angiogenetic 
impact of the surrounding environment (Fehm et al. 2008)
In order for the cancer cell to succeed in developing a late, detectable metastatic 
tumor,	it	must	first	be	able	to	escape	from	the	cohesion	of	its	primary	tumor,	and	
to invade the surrounding stromal tissue. Thereafter, the disseminated tumor cell 
(DTC) must reach the lymph or blood as a circulating tumor cell (CTC), and then 
extravasate to the target organ parenchyma. At this stage, tumor cells have four 
possible	fates:	1)	they	die	(the	vast	majority	of	cells	undergo	apoptosis	or	are	killed	
by immune cells); 2) they can enter a state of quiescence or dormancy – either 
as a single solitary cell, or; 3) as a micrometastatic lesion without the capacity of 
proliferative expansion or they can recruit a vascular bed, or; 4) they can resume 
proliferation and form growing micrometastases. 
Based on cell culture and animal models, dormancy can occur at two different 
levels, as single dormant cells and as micrometastases.  During the dormancy stage, 
sub-clinical disease may be caused by dormant cells that have entered a G0-G1 arrest 
(cellular dormancy), and these cells may develop mechanisms to evade immune 
system recognition and eradication. In the dormancy of micrometastases, there is 
a balance between the proliferation rate and apoptosis, with no net increase in the 
cell number. 
GENETIC AND EPIGENETIC MECHANISMS OF TUMOR DORMANCY
Genetic mechanisms
Earlier,	it	was	thought	that	genetically	fit	tumor	cells	that	emerge	from	the	primary	
tumor (which is proposed to be a late event in cancer progression) are able to 
metastasize (Hanahan et. Weinberg 2000, Talmadge et al. 1982). This was thought 
to be due to the time needed for tumor cells to mutate and acquire traits that allow 
them to pass through the different steps of metastatic development. However, recent 
studies suggest that tumor cell dissemination might occur early (i.e. is, by less 
genetically altered cells) and the disseminated tumor cells then progress towards 
more aggressive phenotypes that lead to metastatic growth in parallel with the 
primary tumor (Schardt et al. 2005). If disseminated tumor cells were to remain 
after treatment in a continuously proliferative phase, the relapse would be expected 
to occur much earlier than is actually observed (Demiceli 2001). Therefore, a 
decline in progressive properties (i.e., dormancy) is considered to be the most likely 
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explanation for the discrepancy between the estimated and observed disease-free 
periods (Demiceli 2001). Tumor dormancy is observed in local recurrences or distant 
metastases. In primary tumors, the term commonly used is latency: the time that 
separates the carcinogenic insult from the clinical detection of the primary tumor. 
With the development of techniques to detect rare cells, including phenotyping 
and genotyping of minimal residual disease, new insights and theories are beginning 
to emerge (Meng et al. 2004, Fehm et al. 2005). Klein et al. (1999) developed a 
PCR strategy which enables a comprehensive analysis of the entire genome on a 
single-cell level. The ectopic localization of epithelial cells in bone marrow by itself 
does not prove their malignant nature. However, comparative genomic hybridization 
(CGH)	and	sequence	findings	from	the	isolated	cytokeratin-positive	cells	indicate	
that these cells are indeed tumor cells (Klein et al. 1999).
When Klein and Hölzel analyzed the genom of DTCs, they found considerable 
differences in chromosomal abnormalities between primary tumors and the tumor 
cells isolated from bone marrow of breast cancer patients without manifested 
metastases (Klein et Hölzel 2006). Indeed, the tumor cells taken from bone 
marrow	harbored	 significantly	 less	 genomic	 aberrations	 than	did	 the	primary	
tumors. For example, only 14% of M0 stage breast cancer patients with single 
chromosomally abnormal DTCs in their bone marrow showed shared aberration 
between primary tumors and the analyzed cytokeratin-positive cells. When the 
authors analyzed the normal-appearing cells at higher resolution for small DNA 
deletions	or	amplifications,	 they	observed	that	most	of	 these	normal-appearing	
cells were indeed tumor cells derived from breast cancer. Therefore, in at least 95% 
of cases, no similarity for chromosomal aberrations could be established between 
the primary tumors and the cytokeratin-positive tumor cells in the bone marrow 
of breast cancer patients (Klein et Hölzel 2006).
 In summary, based on the above observations (Klein et Hölzel 2006), the model 
of	linear	progression	of	cancer	is	challenged	by	the	following	facts:	first,	since	CGH	
detects genetic changes that are present in at least 60% of primary tumor cells, this 
predominant cell population disseminates only exceptionally. Second, since DTCs 
display lower numbers of genetic changes per cell than the abnormalities found in the 
primary tumors, this may mean that they are not derived from the primary tumors in 
the phase present at diagnosis. Rather, they may originate from earlier stages of the 
cancerous lesion. Third, both the reduced relative number of migrating cancer cells 
in large tumors and the absence of typical genetic changes in the DTC population 
suggest that the cells in the primary tumor are highly selected for stationary growth 
and are probably unable to disseminate. Thus there is no evidence for genetically 
more advanced, fully malignant cells leading to human breast cancer metastasis. 
At the time of surgery, more than 95% of disseminated breast cancer cells in the 
bone marrow display either none, fewer or different chromosomal abnormalities, 
compared	to	the	primary	tumor	(Klein	et	Hölzel	2006).	The	findings	from	DTCs	
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suggest that a long time is needed to accumulate genetic changes required for 
metastasis. The cytokeratin-positive single DTCs from patients without manifested 
metastases displayed very different chromosomal changes – as long as the patients 
remained in the stage of minimal residual disease. However, in more than 95% 
of patients who presented metastases, the individually isolated and analyzed 
cytokeratin-positive cells from the bone marrow were highly similar. This suggests 
that tumor cells that have disseminated early are genetically unstable; they diverge 
considerably until one clone acquires genetic abnormalities enabling colonization 
and growth at a distant site (Klein et Hölzel).
The interesting question is: how can a dormant single cancer cell or micrometastasis 
be activated to escape the dormant state and to manifest metastasis? 
The different factors contributing to tumor dormancy can be divided roughly 
into those awakening cells from dormancy, i.e. activating metastatic development, 
and into those suppressing metastatic development and tumor dormancy (Pantel 
et al. 2009) (Table 6). 
Experimental studies on tumor dormancy have disclosed genes that encode the 
MKK4 and Kiss1 metastasis suppressors, as well as Bcl-xL and alpha5beta1 integrin-
fibronectin	as	apoptotic	inhibitors,	and	stanniocalcins	as	survival	factors	(Pantel	
et al. 2009). Analyses of bone marrow and blood from patients with breast cancer 
have revealed that upregulation or re-expression of HER2 and the urokinase-type 
plasminogen activator receptor (uPAR) in DTCs could serve as a switch to interrupt 
dormancy	(Wülfing	et al. 2006, Solomayer et al. 2006).
Epigenetic mechanisms
Although the effects of epigenetic changes on cancer development have been 
extensively	investigated,	their	influence	on	tumor	dormancy	has	not	been	resolved.	
Epigenetic changes, such as pathological methylation patterns, have been postulated 
to occur in an early stage of tumor progression, before chromosomal aberrations 
(Jones et Baylin 2007). Methylation of homeobox genes is a frequent and early 
epigenetic event in breast cancer (Tommasi et al. 2009). Theoretically, it is possible 
that such mechanisms contribute to latency (dormancy) in the development of 
the primary tumor, i.e. the time between the carcinogenic insult and the clinical 
detection of the tumor. 
Research	in	the	past	two	decades	has	found	a	group	of	genes	specifically	targeted	
at	metastatic	suppression.	The	genes	influencing	the	formation	of	distant	metastases	
are distinct from the genes involved in the growth of the primary tumor (Metge et 
al. 2008, Shevde and Welch 2003). Metge et al. showed that BRMS1 (breast cancer 
metastasis suppressor-1) prevents metastasizing of breast cancer and melanoma 
in athymic mice. They showed that the preventive function is down-regulated in a 
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Table 6. Factors regulating the balance between sustaining the dormant state of a tumor (+) or 
escape from dormancy (- onset of metastasis)
Dormancy Protein Effect
+ p16ink4A tumor-suppressing factor
+ MKK4, MAP2K4- mitogen-activated 
protein kinase 4, metastasis suppressor
induces apoptosis, regulates apoptosis 
induced by TNF (tumor necrosis factor) 
+ KISS1, Metastin, metastasis suppressor reduces the activity of the matrix 
metalloproteinase (MMP-9) and 
invasion
+ BRMS1, Breast cancer metastasis 
suppressor
suppresses anti-apoptotic genes 
controlled by NF (necrosis factor) 
-kappa-B
+ Stanniocalcin, STC1 ja STC 2,
glycoproteinlike  hormone
survival and differentation factors 
+ TSP thrombospondin anti-angiogenic factor
+ Type I interferons, IL-7 and IL-15 T-cell survival cytokine, anti-tumor 
T-cell memory
+ p38alpha and/or beta, mitogen activator 
apoptotic/growth suppressive stress-
activated protein kinase 2 (p38)
induce apoptosis, arrest growth, 
promote senescence
+ p53 tumor suppressor, activates p38 
+ Maspin tumor suppressor, apoptotic inducer, 
anti-angiogenic factor, metastatic 
suppressor
- Estrogen cell proliferation, tumor growth
- Progesterone activates breast cancer stem cells
- Bcl-2, Bcl-xL inhibit apoptosis
- alpha5beta1 integrin-fibronectin inhibits apoptosis
- VEGF, vascular endothelial growth factor stimulation of ‘angiogenic switch’ 
- HER2/neu, human epidermal growth 
factor  2, proto-oncogene
encodes the cell membrane receptor 
tyrosine kinase, involved in the signal 
transduction pathways leading to cell 
growth and differentiation 
- uPAR  urokinase receptor regulation of ERK/p38, activation of 
alpha5beta1 integrin
- e-cadherin stimulates the EMT 
- CD44+/CD24-/CK+ stem cell properties
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metastatic disease and that this down-regulation is not caused by deletion of the 
gene, but via epigenetic silencing. This kind of altered methylation of the BMRS1 
gene promoter is an example of epigenetic silencing of gene expression (Metge et 
al. 2008). 
Micro-RNAs
It is becoming accepted that micro-RNAs play a critical role in cancer. Micro-RNAs 
are small (approximately 22 nucleotides long), non-coding RNA molecules, which 
regulate gene expression after transcription. They are post-transcriptional regulators 
that bind to complementary sequences on target messenger RNA transcripts 
(mRNAs), usually resulting in translational repression and gene silencing (Bartel 
2009). 
Micro-RNAs can act as either oncogenes or tumor suppressors in tumor 
development (Nicoloso et al. 2009). Moreover, one micro-RNA can presumably 
affect	the	transcription	of	hundreds	of	target	genes.	Identification	of	micro-RNAs	
associated with tumor dormancy and manipulation of their expression levels could 
lead to prolonging or preventing the dormancy periods. 
The	micro-RNA	molecules	are	tissue-specific.	For	example,	in	epithelial	cancers	
and	lymphomas,	there	are	high	levels	of	mi-155	expression,	and	the	influence	is	
oncogenic, whereas in endocrine tumors this micro-RNA is highly down-regulated 
and possibly has suppressive functions (Calin et Croce 2006). 
The	expression	of	miR-126	and	miR-335	is	lost	in	the	majority	of	primary	breast	
tumors from patients who undergo relapse, and the loss of expression of either 
micro-RNA is associated with poor distant metastasis-free survival. In human breast 
cancer, MiR-335 and miR-126 are thus considered to be micro-RNAs that suppress 
metastasis and support tumor dormancy (Tavazoie et al. 2008). An increasing 
amount of data suggests that micro-RNAs may affect and therefore connect stemness 
and metastasis through the regulation of epithelial-mesenchymal transition (EMT), 
which is a genetic developmental program shared by both phenomena (Nicoloso 
et al. 2009). 
Dormancy and cancer stem cells
The idea that cancer initiates from stem cells goes back to the 19th century concept 
of “embryonic rest”. Already Rudolf Virchow noticed similarities between embryonic 
and cancer tissues (Virchow 1858, Hendrix et al. 2007). They both have the capability 
of renewing and differentiating. Over one hundred years later, the resemblance 
between	this	old	assumption	and	the	theory	of	cancer	stem	cells	was	confirmed.	
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By examining embryonic and hematopoietic stem cells, it has been possible to get 
information on the cell surface marker expression of the stem cells. The cancer 
stem	cell	theory	was	first	proposed	by	Hamburger	and	Salmon,	who	demonstrated	
that only a small percentage of tumor cells were able to form colonies in soft agar 
(Hamburger and Salmon 1977).  
In	1994,	John	Dick’s	laboratory	first	succeeded	in	transferring	a	cancer	stem	
cell (CSC) in an animal model by transplanting an AML-initiating cell into severe 
combined	immune-deficient	(SCID)	mice	(Lapidot	et al. 1994). In 2003, Michel 
Clarke et al.	first	found	cancer	stem	cells	 in	a	solid	tumor	(Al-Hajj	et al. 2003). 
They were able to distinguish the tumorigenic (tumor initiating) from the non-
tumorigenic cells as CD44+CD24-/low-Lineage in eight of nine breast cancer 
patients. As few as 100 cells with this phenotype were able to form tumors in 
mice, whereas tens of thousands of cells with alternative phenotypes failed to form 
tumors	(Al-Hajj	et al. 2003). 
If cancer cells are able to remain dormant for prolonged periods, and if they can 
be reactivated to renewed proliferation, the stem cell properties of dormant cancer 
cells could explain these events. Stem cells can stay dormant for a long time, and 
reversible quiescence might be observed in stem cells or in cells that withdraw into 
a G0 arrest because of lack of growth-promoting signals (e.g., serum withdrawal 
and contact inhibition) (Pelayo et al. 2006, Zhang et al. 2006). 
Stem cells also have the capacity for self-renewal. This is a unique type of cell 
division in which the capacity of one or both daughter cells to proliferate and 
differentiate	 is	similar	 to	those	of	 the	parental	cell	 (Al-Hajj	et Clarke 2004). In 
some patients with early breast cancer, disseminated cytokeratin-positive tumor 
cells can be detected in the bone marrow of patients who never suffer relapse. It 
has been suggested that in these patients, the cancer cells lie dormant until some 
unknown event triggers renewed proliferation. Alternatively, it is possible that 
the DTSs in this group arise from non-tumorigenic cells, and only when CSCs 
disseminate and subsequently self-renew, will the patients relapse with macroscopic 
metastases (Reya et al. 2001).
In addition to the capability of self-renewal, the stem cells are able to protect 
themselves	from	cell	injury	and	achieve	a	long	life	span.	It	has	been	shown	that	
both normal stem cells and cancer cells can resist apoptotic proteins by a number 
of parallel mechanisms, including activation of the Hedgehog (HH) pathway, 
dysregulated transforming growth factor beta (TGF-beta) signalling, and provoke 
other anti-apoptotic proteins, such as members of the Bcl-2 family (Liu et al. 2006, 
Wang et al. 2003).  
Since chemotherapeutic agents are targeted at rapidly dividing tumor cells, 
the non-dividing quiescent stem cells and the dormant tumor cells supposed to 
have stem cell properties are more resistant to chemotherapy. Even therapies that 
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cause complete regression of tumors might spare enough cancer stem cells to allow 
regrowth of the tumor later (Reya et al. 2001).
Both stem cells and supposed dormant cancer cells need a specialised safe place, 
a niche or a microenvironment that contains the signalling molecules required to 
maintain stem cell identity. Such microanatomical niches maintaining stem cells 
have been found in different tissue types (Li and Neaves 2006). The important role 
of these microenvironments is to maintain undisturbed signalling pathways and to 
protect the cell from uncontrolled division and cancer initiation.
Microenvironment and tumor dormancy
Tumor development and progression is dependent on the balance of biochemical 
and	biophysiological	influence	of	the	microenvironment	(Kenny	and	Bissell	2003).	
Already in 1863, Virchow suggested that there is a connection between epithelial and 
stromal cells. In later investigations, the role of stromal cells in the differentiation 
and growth of epithelial cells, and in the prerequisite of their growth, has been 
clarified.	Bone	marrow	offers	a	natural	milieu	for	examining	the	phenomenon	of	
tumor dormancy, since the dormant cells appear to accumulate there. In bone 
marrow, there is a wide spectrum of chemokines and cytokines which contribute 
to wound healing.  Bone marrow also harbors different stem cell lines, such as a 
wide spectrum of mesenchymal stem cells, with the potential to differentiate into 
myofibroblasts,	endothelial	cells,	leukocytes,	and	cells	producing	the	intercellular	
matrix. The interaction between stromal cells, endothelial cells and immunological 
mechanisms	may	 contribute	 to	 changes	 for	 example	 in	fibroblasts,	which	 can	
promote tumor growth and metastasis.
Epithelial-mesenchymal transition (EMT) is an important event in the crosstalk 
between	cancer	and	the	microenvironment.	Changes	that	influence	the	cell	structure	
and adhesional properties, and which facilitate invasion, have been called EMT. In 
breast cancer, e-cadherin is known as a trigger for EMT (Gould and Gould 1999). 
The	fibroblasts	of	the	tumor	induce	EMT	by	secreting	transforming	growth	factor	
(TGF-beta). Thereafter, cancer cells are released due to loosened cell-to-cell contacts 
and proteolytic remodelling of the intercellular matrix. 
Microenvironmental factors contributing to single dormant tumor cells
It has been shown that a large proportion of DTCs remain in distant organs as single 
dormant cells (Goodison et al. 2003, Naumow et al. 2001). This phenomenon may 
be partially mediated by interactions between the tumor cells and the extracellular 
matrix. Furthermore, studies on experimental models have shown involvement of 
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the urokinase-type plasminogen activator receptor (uPAR), the epidermal growth 
factor receptor (EGFR), extracellular signal-regulated kinases (ERK), and p38 in 
the regulation of quiescence-based dormancy of tumors (Aguirre-Ghiso et al. 2001 
, Ranganathan et al. 2006, Allgayer et Aguirre Ghiso 2008).  A balance, regulated 
by uPAR, that favors p38 activation over ERK, can induce persistent dormancy in 
vivo (Raganathan et al. 2006). uPAR seems to be a central regulator of the balance 
between tumor cell proliferation and quiescence in induced tumor dormancy. 
Although uPAR expression correlates with in vivo cell proliferation, uPAR is also 
expressed in DTCs (Allgayer and Aguirre-Ghiso 2008). uPAR expression can 
potentially be used as a predictive marker for clinical prognosis. It was found to be 
associated with higher tumor cell counts in bone marrow and with an unfavorable 
prognosis, also in breast cancer. In addition, the transcription factor ATF6alpha, 
which	is	regulated	in	part	by	p38,	was	 identified	as	a	pivotal	survival	 factor	for	
quiescent dormant tumor cells in vivo (Schewe and Aguirre-Ghiso 2008). 
Systemic	signals	that	influence	both	stromal	and	tumor	cells	may	play	a	role	in	
the	regulation	of	dormancy.	The	hormonal	influence	on	dormancy	has	been	studied	
by transplanting pregnancy-dependent tumors into virgin female mice. Stimulation 
by hormones that are produced during pregnancy, or hormonal treatment, caused 
these tumors to emerge from dormancy (Gatteli et al. 2004).
It is suggested that reduced crosstalk of DTCs with its microenvironment induce 
quiescence or ‘differentiation’ and thus dormancy of tumor cells. Although the DTCs 
in mouse models of experimental breast cancer metastases die, a fraction of them 
remains viable and does not proliferate in other tissue, as lung and liver, but forms 
tumors in orthotopic mammary fat pads (Chambers et al. 2002, Naumow et al. 
2002). It is important to emphasize that at an early stage, solitary dormant tumor 
cells are surrounded by normally functioning tissue vasculature. Therefore, rather 
than invoking a mechanism that depends on neovascularization, it is more likely 
that	deficient	crosstalk	with	the	new	microenvironment	and/or	stress	signalling	
explains the impaired proliferation of these tumor cells.
Angiogenesis-related tumor dormancy
	The	vast	majority	of	tumors	depend	on	recruitment	of	functional	blood	vessels	to	
support the growth of the tumor mass. Tumors that are unable to induce successful 
angiogenesis remain avascular and microscopic in size (Holmgren 1996, Hart 1999, 
Watnick et al. 2003). Tumor cells in avascular dormant tumors typically exhibit a 
high proliferation rate that is balanced by elevated apoptosis (Holmgren et al 1995). 
The transition from a prevascular lesion to a highly vascularized and progressively 
outgrowing tumor is referred to as the “angiogenic switch” (Hanahan et Weinberg 
2000, Baeriswyl et Christofori 2009).
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Tumor cells that form dormant tumors and those forming fast-growing tumors have 
been compared regarding their molecular and cellular characteristics (Almong et al. 
2006, Naumov et al. 2006). Although both dormant and fast-growing tumors contain 
cells that have similar proliferation rates in vitro, they may have strikingly different 
growth kinetics in vivo. In contrast to the fast-growing tumors, which were detectable 
a	few	weeks	after	tumor	cell	injections,	the	dormant	tumors	remained	microscopic	
and	did	not	expand	in	size	for	prolonged	periods	of	time.	A	significant	difference	was	
observed in the structure of the tumor vasculature between dormant and fast-growing 
tumors (Almong et al. 2006, Naumov et al. 2006). In non-angiogenic dormant tumors, 
small clusters of endothelial cells without lumina were commonly observed, indicating 
that the process of tumor angiogenesis was incomplete. Cells from non-angiogenic 
dormant tumors secreted relatively high levels of the potent angiogenesis inhibitor, 
thrombospondin. These experiments indicate that angiogenesis is a necessary event 
for the shift from dormancy and tumor progression.
The immune system and tumor dormancy
It has been known for decades that the immune system has a role in controlling tumor 
growth (Aquirre-Ghiso 2007, Finn 2006, Weinhold et al. 1979, Zou 2005). Studies 
using syngeneic animals that are immunized with a subcutaneous implantation of 
tumor	cells	and	then	challenged	by	intraperitoneal	injection	of	cells	have	shown	
that the immune system can target and kill most of the tumor cells in the challenge 
injection	(Finn	2006,	Weinhold	et al. 1979). The immune responses are mostly 
mediated by cytotoxic CD8+ T lymphocytes, which mediate cytolysis of the tumor 
cells (Finn et al. 2006). However, it seems that some residual cells still persist, and 
this population may be kept clinically dormant by the immune system (Weinhold et 
al. 1979, Matsuzava et al. 1991). Thus, the immune system prevents the expansion 
of proliferating tumor cells.
Additional studies have shown that proliferating mouse lymphoma cells are kept 
at a low number in bone marrow due to persisting antigen and memory T cells that 
are able to coordinate the CD4+ and CD8+ T-cell-mediated response (Mahnke et 
al. 2005, Feuerer et al. 2001, Willimsky et al. 2005). These results are in line with 
clinical studies showing that the bone marrow of breast cancer patients contains 
cytokeratin-positive cells (breast cancer cells), and a higher proportion of memory 
T cells among the CD4+ and CD8+ cells correlated with larger tumors (Feuerer 
et al. 2001). These results suggest that in some situations, the immune system 
might still be operating to suppress residual tumor cell expansion, whereas other 
mechanisms of dormancy favor immune system evasion.
When immunologists in the 1950s gained a deeper understanding of 
transplantation, tumor immunobiology and immunogenetics, Burnet and 
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Thomas (Burnet 1957) developed the immunosurveillance theory. They proposed 
that lymphocyte populations continuously recognize and eliminate cancerous/
precancerous cells in the host before they develop into invasive tumors with 
metastatic potential. 
New studies in the 1990s, encouraged by technological advances in mouse 
genetics and monoclonal antibody (mAb) production, reinvigorated and ultimately 
validated the concept of cancer immunosurveillance (Smyth et al. 2001 b, Dunn 
et al. 2004, Dunn et al. 2002) and expanded it to incorporate the contributions of 
both innate and adaptive immunity.
However, immunosurveillance represents only one dimension of the complex 
relationship between the immune system and cancer (Dunn et al, 2002, 2004, 
Screiber et al. 2004). The immune system is capable of sculpting the cancer 
phenotype	 by	 interacting	 with	 tumors.	 Tumor	 cells	 can	 be	 modified	 to	 less	
immunogenic variants which can escape immune recognition and destruction 
(Teng et al. 2008).
These	 findings	 prompted	 the	 development	 of	 the	 cancer	 immunoediting	
hypothesis to more broadly encompass the potential host-protective and tumor-
sculpting functions of the immune system throughout tumor development (Dunn 
et al. 2002, 2004).
Cancer immunoediting is a dynamic process composed of three phases: 
elimination, equilibrium, and escape. Elimination represents the classical concept 
of cancer surveillance, where cells and molecules of the innate and adaptive 
immune systems may eradicate the developing tumor and protect the host against 
tumor formation. However, if this process is not successful, the tumor cells may 
enter an equilibrium phase where they may either be maintained chronically or 
immunologically sculpted by immuno-‘editors’ to produce new populations of tumor 
variants. The equilibrium is the period of immune-mediated latency (dormancy) 
after incomplete tumor destruction in the elimination phase. Escape refers to the 
final	outgrowth	(awakening	from	dormancy)	of	tumors	that	have	outstripped	the	
immunological restrains of the equilibrium phase.
MARKERS ASSOCIATED WITH TUMOR DORMANCY
Stanniocalcins (STC-1 and STC-2)
Stanniocalcin-1 (STC-1) is a glycoprotein that is highly conserved in vertebrates 
–	from	fish	to	mammals	(Chang	et al.	2003).	In	fish,	 it	 functions	as	a	classical	
hormone, regulating calcium and phosphate homeostasis and protecting against 
toxic hypercalcemia (Wendelaar Bonga and Pang 1991, Lu et al. 1994).
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 There is, however, no evidence that the mammalian homolog STC would have 
any physiological role in regulating serum calcium. Instead, mammalian STCs are 
expressed in a variety of tissues. STC-1 is particularly expressed in cells undergoing 
terminal postmitotic differentiation, such as brain neurons (Zhang et al. 1998), 
adipocytes (Serlachius et Andersson 2004), striated muscle (Jiang et al. 2000) 
and megakaryocytes (Serlachius et al. 2002).  STC-1 is also found in heart, bone 
(Serlachius et al. 2002), kidneys and ovaries (Worthington et al. 1999). Expression 
of STC-2 has been found in kidney, heart, pancreas and spleen (Chang and Reddel 
1998, Ishibashi et al. 1998, DiMattia et al. 1998).
STC-1 and STC- 2 expression has also been found in neoplastic mammary tissue 
and a correlation between ER expression and the presence of STC-1 and STC-2 has 
been shown in breast cancer (Bouras et al. 2002). 
The physiological functions of stanniocalcins in mammalians are incompletely 
understood. STC-1 is reported to localize to mitochondria, and it induces enhanced 
electron transport in submitochondrial particles. Furthermore, STC-1 is regulated 
by the tumor suppressors BRCA1 (Welcsh et al.2002) and p53 (Lai et al. 2001). 
STC1 and STC2 have also been found to act as survival factors and to protect the cell 
against hypoxic and hypercalcemic stress, particularly in terminally differentiated 
slowly proliferating cells (Zhang et al. 2000). High expression of STC-1 was detected 
in slowly proliferating, well-differentiated, low-grade liposarcomas, whereas high-
grade liposarcomas did not express STC-1 (Serlachius et Andersson 2004). Exposure 
of mice to low oxygen levels was shown to upregulate STC-1 in the brain via IL-6 
dependent signalling (Westberg et al. 2007). Stanniocalcins may thus be regarded 
as tumor-suppressive factors.
There is also evidence that stanniocalcins have tumor-progressive properties. The 
growth of solid tumors, such as breast cancers, is usually associated with hypoxia and 
endoplasmic reticulum stress. STC-2 promotes cell proliferation under hypoxia, and 
is a hypoxia-inducing factor-1 (HIF-1)-responsive gene. It has been demonstrated 
that the epigenetical silencing of STC-2 may interfere with HIF-1-mediated activation 
of STC-2 expression, since STC-2 was aberrantly hypermethylated in human ovarian 
epithelial cancer (SKOV3) cells (Law et al. 2008). 
Recently, new insight has been reported on the relation of STC-1 to breast cancer, 
as protein kinase Calpha (PKCalpha) suppresses the expression of STC-1 mRNA in 
MDA-MB-231 breast cancer cells (Cornmark et al. 2011). High levels of PKCalpha 
correlate with an aggressive breast cancer phenotype and predict poorer survival 
(Lonne et al. 2010).  
STC-1 has been associated with both antiapoptotic (Zhang et al. 2000) and 
cell death-inducing effects (Nguyen et al. 2009). Stanniocalcin may therefore have 
either pro- or anti-tumorigenic effects, depending on the cellular context. As a 
consequence, the stanniocalcins can either function as tumor dormancy-supportive 
or recurrence/metastasis-activating factors.
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p53
The p53 tumor suppressor gene has a regulatory function in defending against 
various kinds of cancer, including breast cancer (Attardi et Donehower 2005, 
Børresen-Dale 2003, Meek 2009). p53 is regarded as a central player in tumor 
suppression. It senses DNA damage and responds by inducing a transient growth 
arrest, allowing DNA repair or, in the case of extensive damage, promoting 
irreversible growth arrest (senescence) or programmed cell death (apoptosis) (Lowe 
et al. 2004, Vousden 2009). 
The critical role of p53 in the prevention of cancer development is demonstrated 
by the presence of mutated p53 in approximately 50% of human cancers (Hollstein 
et al 1991). The frequency of p53 mutations in breast cancer ranges from 15 to 
71% (Borresen-Dale 2003). The simplest way to measure p53 function is to look 
for its overexpression by IHC with an antibody to p53. Wild type p53 is normally 
rapidly degraded, but most p53 mutations, even as they disrupt function, lead to 
accumulation of the protein that is strongly reactive with antibodies to p53 (Bartley 
and Ross 2002). Although most studies have shown a poorer prognosis for breast 
cancers with increased p53 expression (Thor and Yandell 1993, Allred et al. 1993, 
Kovach et al. 1996, Blaszyk et al. 2000), some studies have found no correlation 
between prognosis and p53 expression (Isola et al. 1992, Reed et al. 2000, Pietiläinen 
et al. 1995). 
Given that p53 is inactivated in almost all types of human cancers, a number 
of innovative therapeutic strategies have been developed to restore p53 function in 
cancer (El-Deiry 2003, Nikitina et al. 2002). p53 may play a role in an angiogenic 
tumor dormancy experiment.  Angiogenic dormancy results from the balance 
between pro- and anti-angiogenic factors (such as vascular endothelial growth 
factor (VEGF) and thrombospondin (TSP), respectively. Genetic alterations in the 
pathways that maintain angiogenic dormancy or an exogenous angiogenic ‘spike’ 
might restore tumor growth. Oncogenic Ras can induce expression of VEGF and 
repress TSP. In contrast, the stress-activated kinase p38 and the tumor suppressor 
p53 can induce TSP or repress VEGF. Loss of function of p53 and/or p38 might 
tip the balance towards enhanced angiogenesis and awakening from dormancy 
(Aguirre-Chiso 2007).  
Bcl-2
Bcl-2 is a member of a family of cytoplasmic proteins (the Bcl-2 family) whose 
transcription	is	regulated	by	p53.	Bcl-2	was	first	discovered	in	B-cell	lymphomas	
in which, as a result of a chromosomal translocation t (14, 18), the Bcl-2 gene 
is	 juxtaposed	to	the	immunoglobulin	heavy	chain	gene	(Chen-Levy	et al. 1989). 
This alteration drives constitutive expression of Bcl-2, which localizes to the inner 
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mitochondrial membrane and blocks programmed cell death (Hockenbery et al. 
1990). According to a study by Joensuu et al., expression of the oncoprotein Bcl-
2 (B-cell lymphoma-2) in breast cancer is associated with a favorable prognosis 
(Joensuu et al. 1994). The reason for the apparently paradoxical favorable prognostic 
impact of Bcl-2 on breast cancer is not clear. Knowlton et al. (1998) showed 
that expression of Bcl-2 retards the cell cycle of breast cancer cells. A decreased 
proliferation rate of tumor cells may thus account for the association of Bcl-2 
expression with a favorable outcome in breast cancer. 
As an anti-apoptotic protein, Bcl-2 belongs to the factors which should support 
metastatic progression and escape from tumor dormancy (Pantel et al. 2009). 
Maspin
Maspin is a mammary serine protease inhibitor (SERPINB5) with tumor suppressor 
activity,	first	 isolated	 from	normal	mammary	epithelial	 cells	 (Zou	et al. 1994). 
The mechanism underlying the biological activity of maspin is largely unknown. 
Contradictory results have been reported on the role of maspin in breast cancer 
and its prognostic impact. Some earlier studies on maspin demonstrate its tumor-
suppressive properties (Sheng et al. 1996, Zhang et al. 1997). In breast cancer, 
the tumor suppressor activity of maspin was attributed to its ability to inhibit cell 
motility, invasion and metastasis (Maass et al. 2001). High levels of maspin are 
also associated with decreased angiogenesis (Zhang et al. 2001). Maspin-mediated 
reduction of tumor growth is at least partially attributed to the enhancement of 
apoptosis (Liu et al. 2004, Zhang et al. 2005).  
Contradictory	findings	on	the	function	of	maspin	in	breast	cancer	have,	however,	
also been published. Umekita et al. reported that expression of maspin in breast 
cancer	was	associated	with	significantly	shorter	relapse-free	survival	(Umekita	et 
al. 2002), and that the expression of maspin is upregulated during the progression 
of ductal breast carcinoma (Umekita et Yoshida 2003). In breast cancer, Mohsin et 
al. (2003) showed that nuclear immunopositivity for maspin was associated with 
a favorable prognosis, such as ER and PR positivity, whereas cytoplasmic staining 
was related to ER and PR negativity. However, there is no certainty of whether 
the different cellular location of maspin protein, either nuclear or cytoplasmic, is 
of functional importance. 
Maspin is not mutated or rearranged in tumor cells, but the gene is epigenetically 
silenced during metastatic transaction by aberrant cytosine methylation of the 
maspin promoter (Domann et al. 2000). The reversible nature of epigenetic silencing 
of	maspin	offers	a	unique	opportunity	for	therapeutic	interventions	through	specific	
re-activation of the endogenous gene. (Beltran et al.2008). 
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Several chromatin-remodelling drugs have been developed to release the 
repressed state of tumor suppressor genes. These drugs act by inhibiting DNA 
methyl transferases or histone deacetylases (HSAC), resulting in increased promoter 
accessibility and enhanced tumor suppressor gene transcription (Cameron et al. 
1999, Oshiro et al. 2003, Hellebrekers et al. 2007). 
Because maspin displays tumor suppressor properties, and inhibits breast cancer 
cell motility, invasion, metastasis and angiogenesis, it most probably functions as 
a supportive factor in tumor dormancy.
Bmi-1
Bmi-1 belongs to the mammalian polycomb group (PcG) of proteins. They form 
multimeric	complexes	that	regulate	gene	activity	at	the	chromatin	level	(Satijn	et 
al. 2001). Bmi-1 contributes to cell cycle regulation by acting as a transcriptional 
repressor of the INK4a/ARF (=human p19ARF) locus (Jacobs et al. 1999).
Kim et al. (2004) demonstrated that overexpression of bmi-1 transcripts and 
Bmi-1 protein in breast cancer correlated with axillary lymph node metastases. They 
suggested that cell cycle deregulation by Bmi-1 might play a role in the progression 
of	breast	cancer	and	lymph	node	metastasis.	Al-Hajj	et al. (2003) described the 
existence of a cancer stem cell population in human breast cancers. These cancer 
stem cells displayed increased expression of Bmi-1 (Liu et al. 2006).
Expression of Bmi-1 contributes to the stem cell phenotype. Such cells can settle 
down in a non-proliferative dormant state and preserve the properties of self-renewal 
and the possibility to metastasize even long after treatment of the primary tumor 
(Pantel et al. 2009).
c-myc
Bishop and co-workers discovered c-Myc in the late 1970s (Bishop 1982, Vennstrom 
et al. 1982). c-Myc is a DNA-binding, nuclear transcription factor involved in the 
regulation of the cell cycle (Rabbits et al. 1985), programmed cell death, and 
tumorigenesis (Harrington et al. 1994, Amundadottir et al. 1995).
	c-Myc	was	first	detected	in	Burkitt’s	lymphoma,	but	has	later	been	connected	
to many other cancers, including breast and colon cancer, neuroblastoma, 
osteosarcoma, and melanoma (Pelengaris et al. 2002).
The clinical relevance of the overexpression of c-myc protein in breast cancer is 
not well known (Rodriguez-Pinilla et al. 2007, Liao et Dicson 2000). On the other 
hand, MYC	gene	amplification	has	been	associated	with	a	high	histological	tumor	
grade, the presence of lymph node metastasis, a lack of PR, and poor survival in 
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breast cancer (Deming et al. 2000, van Lohuizen et al. 1991).  Bmi-1 has an impact 
on c-Myc activity and vice versa; both of these oncogenes are able to immortalize 
certain cells (van Lohuizen et al. 1991, Haupt et al. 1993, and Levy et. al. 1993).
The Myc gene regulates apoptosis and downregulates Bcl-2, which mediates 
apoptosis-inducing effects and suppresses the onset of metastasis. c-Myc can also 
repress thrombospondin-1 expression and increase angiogenesis by cooperative 
activity with Ras (Watnick et al. 2003) and thereby support the onset of metastasis 
and escape from tumor dormancy.
Snail
Snail	is	a	zinc-finger	transcription	factor	essential	for	EMT.	It	downregulates	the	
expression of cell adhesion and basement membrane proteins, most importantly 
cadherins (Battle et al. 2000). Snail increases migration and invasion in various 
physiological and pathological conditions (Battle et al. 2000, Cano et al. 2000, and 
Peinano et al 2007). The involvement of Snail in tumor progression is supported 
by	findings	 of	 Snail	 expression	 in	 carcinoma	 cell	 lines	 that	 have	 invasive	 and	
metastatic properties (Cano et al. 2000, Cheng et al. 2001, Poser et al. 2001) 
and in de-differentiated breast cancer, and hepatocellular carcinoma (Blanco et 
al. 2002, Sugimachi et al. 2003). Snail is required for tumor growth and lymph 
node metastasis of heterotransplanted human breast carcinoma MDA-MB-231 cells 
(Olmeda et al. 2007).
Yook et al. have reported WNT-dependent regulation of Snail functionality in 
breast cancer cells. WNT signalling can induce increased expression of Axin2, leading 
to the redirection of GSK-3B to the cytosol, leaving Snail in its non-phosphorylated, 
transcriptionally active form (Yook et al 2006). Angiopoietin 2 (Ang2), a growth 
factor, promotes tumor angiogenesis and has been previously shown to increase 
nuclear Snail1 expression, downregulates E-cadherin, and increases the metastatic 
potential of primary breast cancers (Imanishi et al 2007). 
CK5
Keratin	filaments	constitute	a	group	of	8-nm	fibres	that	form	an	integral	part	of	the	
cytoskeleton of eukaryotic epithelial cells (Lersch et Fuchs 1988). There are more 
than 20 different human keratins encoded by a large multigene family, which can 
be divided into two distinct sequence classes, Type I and Type II. Type I keratins are 
small (40 to 56.5 kDa), while Type II keratins are larger (53 to 67 kDa). Cytokeratin 
5 and its pair, cytokeratin 14, are expressed abundantly in the basal layer of the 
epidermis (Lersch et Fuchs 1988).
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In normal breast, both luminal epithelial and the myoepithelial cells exhibit 
different and distinctive keratins. The luminal cells express CK7, 8, 18 and 19, while 
smooth muscle actin (SMA) and CKs 5, 14 and 17 are found in the myoepithelial/
basal cells (Taylor-Papadimitriou et al. 1989).  
The IHC expression of CK5 can be used to identify basal-like carcinomas in 
tissue	sections	(Banerjee	et al.	2006,	van	de	Rijn	et al. 2002). 
Abd El-Rehim et al. (2004) examined a tissue microarray from a large cohort 
of breast cancers. They observed that the tumors expressing the luminal markers, 
CKs 7, 8, 18 and 19, associated with a good prognosis, in contrast to the tumors 
expressing basal markers, particularly CK5, which were associated with a poor 
outcome (Abd El-Rehim et al. 2004).
Possibilities for application of dormancy mechanisms in cancer treatment
Identification	of	the	different	mechanisms	underlying	tumor	dormancy	has	given	
researchers tools for therapeutical interventions to prevent cancer recurrence. 
Because DTCs are already present in the target organs after primary tumor 
removal, and cancer cells can coexist in different states in the metastatic organ, 
they represent very different therapeutic targets. Metastatic cells can be present 
as dormant, quiescent solitary cells, dormant pre-angiogenic micrometastases, and 
actively growing vascularized metastases (Goss et Chambers 2010).
Preclinical models have shown that cytotoxic chemotherapy effectively inhibits 
the growth of metastases, but has no effect on the dormant cells residing in the 
same organ in a liver metastasis model of breast cancer (Naumov et al. 2003).
In an experiment using mouse mammary carcinoma cell lines, treatment with 
doxorubicin reduced the size of large metastases, but did not reduce the number of 
solitary dormant cells (Naumov et al. 2003). Although quiescent, dormant cells are 
difficult	to	kill,	it	could	be	possible	to	tackle	them	after	they	have	reinitiated	growth.
Ongoing clinical trials in hormone-dependent breast cancer suggest that anti-
strike therapies introduced late in follow-up can reduce delayed clinical recurrences. 
The Letrizole after Tamoxifen in Treating Women with Breast Cancer (NCIC CTC 
MA17)	trial	demonstrated	a	significant	 improvement	 in	disease-free	survival	 in	
early	breast	cancer	by	extending	adjuvant	(postoperative)	endocrine	therapy	with	
an aromatase inhibitor, letrozole, for an additional 5 years after the initial 5 years 
of tamoxifen treatment (Goss et al. 2003).
The antibody to HER2, trastuzumab (Herceptin), is an example of a drug that 
targets	signal	transduction,	and	it	can	be	exploited	in	adjuvant	therapy	in	early	
HER2-positive breast cancer. When trastuzumab was given concomitantly with 
paclitaxel	or	after	chemotherapy	for	12	months	as	adjuvant	treatment,	it	reduced	
significantly	the	risk	of	recurrence	(Joensuu	et al. 2009). The Tykerb Evaluation 
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After Chemotherapy (TEACH) trial is investigating the natural history of dormancy 
in HER2-positive breast cancer (Goss et Chambers 2010). 
One candidate for a tumor dormancy markers is the mitogen activated protein 
kinase p38.  Aguirre-Ghiso et al.	(2001)	studied	the	role	of	p38	in	immunodeficient	
chick embryos using human epidermoid carcinoma Hep3 cells. p38 is highly 
expressed in dormant human carcinoma (Hep3) cells and it plays a critical role in the 
induction of tumor dormancy (Ranganathan et al. 2006, Adam et al. 2009). When 
p38 activity was inhibited by pharmacological (SB203580) or genetic (dominant 
negative-p38) approaches, dormancy was interrupted. 
Interestingly, tamoxifen treatment can activate p38 signalling and quiescence 
(Buck et al. 2004), suggesting that tamoxifen ‘dormancy’ treatment could be 
considered as a maintenance therapy to prevent DTCs from exiting their state 
of growth arrest (i.e. dormancy maintenance) or by inducing growth arrest 
(i.e. dormancy induction). However, such a strategy might be selective for ER-
negative tumor cells (Goss et Chambers 2010). p38 inhibitors (such as SCIO-469, 
RO4402257, PH-797804, SB681323 and BMS-5) are currently used in clinical trials 
to treat several neoplastic and non-neoplastic diseases (http://www.clinicaltrials.
gov.)
While	DTCs	are	already	in	the	target	organs	after	primary	surgery,	adjuvant	
therapy should target not only individual tumor cells, but also the surrounding 
microenvironment. One such treatment option is offered by Bisphonates, which are 
potent inhibitors of osteoclast-mediated bone resoprtion. Bisphosphonates inhibit 
osteoclast precursor cells, induce apoptosis of osteoclasts, and alter the growth 
factor and cytokine secretion of the microenvironment. They also reduce tumor 
cell adhesion, induce apoptosis in tumor cells, have an anti-angiogenic effect and 
increase anti-tumor activity of cytotoxic agents (Fehm et al. 2008, Santini et al. 
2003).
Micrometastases found in bone marrow are known to worsen the prognosis – 
their presence at the time of the diagnosis predicts later recurrence of cancer, but 
not necessarily in bone marrow!
An interesting strategy in preventing cancer recurrence may be the use of cancer 
vaccines (Curigliano et al. 2007). Individuals are believed to have cytotoxic T-cell 
precursors	specific	for	tumor-associated	antigens	(TAA)	and	it	is	assumed	that	the	
patient’s immune system can be sensitized to TAAs of the patient’s own tumor. TAAs 
(e.g. CEA, HER2, MUC-1) recognized by the immune effector cells have already 
been	identified	and	used	for	preparing	TAA-dependent	vaccines	(Ko	et al. 2003). 
It	would	be	highly	desirable	to	find	a	simple	indicator	that	allows	risk	assessment	
of late breast cancer recurrence and metastasis development. In contrast to predictors 
based on tumor characteristics at the time of surgery, serum is a particularly valuable 
source, because it is useful not only for the initial screening for the disease but also 
for continuous monitoring of the therapeutic effect. 
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The newly developed antibody microarray-based technology, which enables the 
simultaneous detection of multiple proteins in serum, has been recently exploited to 
predict the development of distant metastases in breast cancer patients. Carlsson et 
al.	(2011)	identified	a	21-protein	signature	from	240	sera	of	64	patients	with	primary	
breast cancer. They were able to assess the risk of developing distant recurrence 
after the primary operation for each patient, using her molecular portrait. This risk 
assessment	was	not	dependent	on	the	type	of	adjuvant	therapy	given	to	the	patients.
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AIMS OF THE STUDY 
This thesis was undertaken to clarify the phenomenon of tumor dormancy in breast 
cancer. In order to achieve this purpose, a retrospective set of primary breast cancers 
and their corresponding early and late relapses were collected.
Factors known to have a role in tumor dormancy, either with activating (escape 
from dormancy) or suppressing (supporting dormancy) properties to develop cancer 
metastases, have been included in this study. 
The	specific	aims	in	these	tumor	series	were:
- to investigate the relationship between tumor dormancy and the established 
biomarkers, ER, PR, HER2, Ki67, used for the clinicopathological treatment 
decision (Study IV) 
- to investigate whether the expression patterns of stanniocalcins (STC-1 and 
STC-2) are in agreement with their presumed roles in cell survival and in 
supporting tumor dormancy (Study I)
- to investigate the expression of the tumor suppressive factors maspin and p53, 
and the antiapoptotic/dormancy-inhibiting factor Bcl-2, and their association 
with early or late tumor recurrence (Study II)
- to investigate whether proteins with stem cell properties – Bmi-1, c-myc and 
Snail – have the potential to activate tumor growth after prolonged tumor 
dormancy (Study III)
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MATERIALS AND METHODS 
PATIENTS AND TUMORS
We collected cases of female patients who had had relapsed breast cancer, and for 
whom	representative	paraffin-embedded	tumor	samples	from	both	their	primary	
tumor and the corresponding recurrent/metastatic lesion were available. The cases 
and the clinicopathological information on the patients were derived from the 
database of the Department of Pathology, Helsinki University Hospital. Recurrence/
metastasis	was	defined	as	any	local	or	regional	recurrence	or	any	distant	metastatic	
disease. We selected the cases according to the time of relapse, and divided them 
into three groups: in Group 1, recurrences/metastases were detected within 2 years, 
in Group 2, at 5–10 years, and in Group 3 after 10 years (range, >10 up to 23 
years).	Only	tumors	of	epithelial	origin,	 i.e.,	 the	major	type	of	malignant	breast	
tumors, were included in the study. The patients had undergone breast cancer 
surgery during 1974–2006. 
Paraffin-embedded	 tissue	blocks	were	collected	 from	altogether	73	primary	
breast cancers and their respective recurrent/metastatic lesions from the archives 
of the Department of Pathology, Helsinki University Hospital. The histological tumor 
type and grade were assigned according to the criteria of Elston and Ellis (1991).
The information of clinicopathological characteristics of the patients and their 
cancers are summarized in Table 7. The Ethics Committee of the Helsinki University 
Central Hospital approved the study protocol.  
IMMUNOHISTOCHEMISTRY 
Four	µm	thick	sections	of	paraffin-embedded	breast	cancer	tissue	were	deparaffinized	
in xylene and rehydrated. Antigen retrieval was done by microwaving in 10 mM 
citric acid monohydrate for 5 min at 900 W and for 3 x 5 min at 600W. Endogenous 
peroxidase activity was blocked by treatment with 0.5% H2O2. The slides were 
incubated overnight in a refrigerator at + 4° C with appropriate dilutions of the 
primary antibodies. The same procedure was used for negative controls, except that 
the overnight incubation took place in PBS diluent without antibody. The reaction 
was visualized by the Elite ABC Kit (Vectastain, Vector Laboratories, Burlingame, 
CA, USA) for PR and ER, Stanniocalcin 1 and 2 and maspin.  HER2 and p53 staining 
was performed using the Envision kit (Dako, Copenhagen, Denmark). 
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Table 7.  Clinicopathological parameters of the 73 breast cancer patients and the tissue site of the 
metastatic recurrence of their tumors. The patients are divided into Groups 1, 2 and 3 
according to the time of relapse after primary diagnosis
Group 1 n=19 Group 2 n=33 Group 3 n=21
Age at surgery of primary tumor
< 50 years 10 14 13
≥ 50 years  9 19 8
Surgery
Mastectomy 18 20 13
Partial mammary resection 1 11 8
Axillary lymph node evacuation 17 31 20
No axillary evacuation 1
Tumor size
< 20 mm 3 16 12
> 20 mm 16 17 9
Lymph node
negative 3 20 11
positive 16 13 10
Grade
1 0 5 3
2 8 19 14
3 11 9 4
Histological type
ductal 16 27 12
lobular 3 5 9
mucinous 0 1 0
Tissue site of metastasis
skin 5 8 11
soft tissue 6 11 6
subcutaneous tissue 0 5 2
lung 0 4 0
lymph node 1 0 0
liver 5 1 0
brain 2 2 0
bone 0 1 1
ovary 0 1 0
stomach 0 0 1
Note. In Group 1, metastatic recurrences were detected within 2 years; in Group 2, from 5–10 years; and in Group 3, 
after 10 years.
Breast surgery data are not available in two cases of Group 2. Axillary evacuation data were not available in one case 
of Group 1, in one case of Group 2 and in one case of Group 3.
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The slides for Bmi-1, c-myc, and Snail immunolabeling were pretreated in a 
PT-module (LabVision UK Ltd, UK) in Tris-HCl buffer (pH 8.5) for 20 min at 
98°C and with 0.3% Dako REAL Peroxidase-blocking solution for 5 min to block 
endogenous peroxidase. Immunostaining was done by incubating each antibody 
for 1 h, followed by 30-min incubation with Dako REAL EnVision/HRP secondary 
antibodies.	The	bound	antibodies	were	finally	visualized	by	Dako	REAL	DAB+	
Chromogen reaction for 10 min. The slides were washed between each step with 
PBS-0.04% Tween20. The antibodies used, their dilutions and the manufacturers 
are presented in Table 8. 
The	result	was	quantified	as	the	proportion	of	positively	stained	tumor	cells	
(range,	0–100%).	For	the	analyses,	the	tissue	samples	were	classified	as	positive	
for	ER	and	PR,	when	≥	10%	of	the	tumor	cells	showed	positive	nuclear	staining	in	
Studies	I,II	and	III.	In	Study	IV,	the	tissue	samples	were	classified	positive	when	
≥	1%	(Hammond	et al. 2010) of the tumor cells showed positive nuclear staining. 
The 1% cut-off was also used for CK5 (Haughian et al. 2011).  
Table 8. List of the antibodies, the laboratories manufacturing them, the dilutions used in IHC staining, 
and the cut-off (≥%) points for Pearson’s Chi-square tests
Antigen Antibody Laboratory Dilution cut-off ≥%
ER 
alpha
Mouse monoclonal clone 6F11 Novo Castra, 
Newcastle, UK
1:50 1% (Study IV), 10% 
(Studies I,II,III)
STC-1 Polyclonal ref. Olsen et al. 1996 1:1500 10%
STC-2 Polyclonal ref. Olsen et al. 1996 1:1600 10%
Maspin Mouse monoclonal clone 
G167-70
B.D. PharMingen, 
San Diego, CA, USA
1:1000 10%
Bcl-2 Mouse monoclonal clone 124 Dako Cytomation, 
Glostrup, Denmark
1:25 10%
p53 Mouse monoclonal clone DO-7  Dako Cytomation, 
Glostrup, Denmark
1:100 10%
Bmi-1 Mouse monoclonal clone 
ab14389
Abcam, Cambridge, 
UK
1:400 10%
c-myc Mouse monoclonal clone 9E10 Santa Cruz, UK 1:400 10%
Snail Polyclonal rabbit clone 
ab17732
Abcam, UK 1:2000 80%
PR 
alpha
Mouse monoclonal clone 
PgR636
Daco Cytomation 
Denmark
1:100 1% (Study IV), 10% 
(Studies I,II,III
HER2 Mouse monoclonal clone CB11 Novo Castra, UK 1:700 Wolff et al. 2007
Ki67 Mouse monoclonal clone MIB-1 Daco Cytomation 
Denmark
1:75 14%
CK5 Mouse monoclonal          
XM26
Leica, UK              1:100 1%
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The IHC scoring method used for HER2 was based on the intensity and 
percentage of positive cells, giving a score between 0 and 3+. Cases were reported 
as 0 (negative) if no staining or membrane staining in less than 10% of invasive 
tumor cells was seen. A 1+ (negative) result was reported if faint/barely perceived 
membrane staining was detected in more than 10% of invasive tumor cells. The 
scoring report was 2+ (positive), if weak to moderate complete membrane staining 
was seen in more than 10% of tumor cells, or < 30% with strong complete membrane 
staining. A 3+ (positive) result was reported, if strong complete membrane staining 
in more than 30% of invasive tumor cells was seen. (Wolff et al. 2007).  The tumor 
was	considered	positive	 for	Ki67,	 if	≥14%	of	 the	 tumor	cells	 showed	positively	
stained nuclei (Cheang et al. 2009). 
A cut-off point of 10% of positivity was used for stanniocalcins (Bouras et al. 
2002), maspin, Bcl-2, p53 (Elledge et al. 1998), Bmi-1(Kim et al. 2004) and c-myc 
(Pavelic et al. 1992). For Snail, the tumors were divided into high- and low-expressing 
groups, using a proportion of 80% of positively stained cells as the cut-off point 
(Häyry et al. 2008). 
We evaluated the entire tumor area from one representative section of the 
primary tumor and metastasis. The results were scored independently by two 
pathologists (KJ, PH). The antibody clones and the laboratories manufacturing 
them, as well as the dilutions that were used for each antibody, and the cut-off 
(≥%)	points	for	Pearson’s	Chi-square	tests	are	shown	in	Table	8.
IHC SUBTYPES
For	 analysing	 the	 subtype	 approximations	 to	 the	 subtypes	 defined	 by	 genetic	
array testing, the tumors were divided to seven subtypes by using IHC: luminal 
A (ERorPR+HER2-, luminal B (ERorPR+HER2+), HER2 overexpressing (ER-
PR-HER2+). triple-negative (ER-PR-HER2-), basal-like (ER-PR-HER2-CK5+), 
unclassified	(ER-PR-HER2-K5-),	luminobasal	(ERorPR+CK5+).	
CHROMOGENIC IN SITU HYBRIDIZATION (CISH) 
CISH was performed on all tumors with protein overexpression of HER2 (2+ and 
3+) by IHC. 
The	slides	with	4	µm	paraffin	sections	were	preheated	at	+55-58°C	for	about	
2–6 h and then dried overnight at 37°C, to avoid detachment. Thereafter they were 
deparaffinized	in	xylene,	rehydrated,	and	incubated	in	Tris-EDTA	buffer	(pH	9.0)	
for 25 min at 98°C. After digestion in 0.1% trypsin for 40 sec, the slides were post-
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fixed	in	10%	formalin	for	10	min	and	dehydrated	in	an	increasing	alcohol	series.	
Then 0.4 ml digoxin-labeled ZytoDotSPECHER2 probe was applied, sealed and 
denatured on a heat plate at 95° for 4 min. Finally, the slides were incubated at 37°C 
overnight for hybridization. On the second day, the slides were opened and washed 
in	78°C	standard	saline	citrate	for	2	x	2	min	to	remove	the	unspecifically	bound	
probe. The digoxigen-labeled HER2 probe was recognized by the primary mouse 
monoclonal	antibody	(clone	1.71.256,	cat	no.	11333062910,	Roche),	and	the	amplified	
signals were visualized with DAB. Immunodetection was performed in a LabVision 
autostainer using the PowerVision Poly-HRP IHC Detection kit (DPVB+110DAB/
ImmunoVision Technologies Co). The slides were then counterstained with Mayers 
Hematoxylin and covered.  
The stainings were examined under a light microscope (40 x); small dots (signals) 
in the nuclei represented the gene copies. We considered 5 or less signals as no 
amplification,	6–10	signals	as	low	amplification,	and	more	than	10	verified	signals	
as	high	amplification.	Stromal	cells	with	the	normal	two	gene	copies/nucleus	served	
as	a	negative	control.	The	amplified	cells	should	represent	at	least	10%	of	the	entire	
tumor.	In	the	case	of	low	amplification,	the	chromosome	17	centromere	probe	was	
used to determine whether the extra copies are caused by chromosomal aneuploidy. 
In these cases, the HER2 status was set as the ratio of the average number of HER2 
gene copies to the average number of copies of chromosome 17. If the average HER2/
Chr17	was	≥	2,	the	result	was	interpreted	as	positive	for	HER2	gene	amplification.	
Stromal cells with the normal two gene copies/nucleus served as a negative control. 
The	amplified	cells	should	represent	at	least	10%	of	the	entire	tumor.	
STATISTICAL METHODS
All statistical analyses were performed using SPSS 13.0 for Windows (SPSS 
Incorporation, Chicago, ILL, USA). The differences between the primary tumors 
and their corresponding metastases were analyzed by the paired samples t-test 
in Studies I, II, III and IV.  For comparing differences between the groups, the 
independent samples t-test was used in Study I. In Studies II and III, Kruskal-Wallis 
and Mann-Whitney U-tests were used for comparing the groups. In Study IV, the 
differences between the groups were analyzed by using the categorical two-tailed 
Pearson’s Chi-square test in univariate analyses, and in Study IV the regression 
ordinal test was used for multivariate analysis.  For comparing the expression of 
the different proteins, the categorical two-tailed Pearson’s Chi-square test was used. 
Probability values of p	>	0.05	were	considered	significant	in	all	analyses	except	in	
Mann-Whitney U-tests, were a p	value	<	.0167	(=<.05/3)	was	considered	significant.
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RESULTS
This study investigated the expression of different biomarkers known to contribute to 
the progression of breast cancer. These biomarkers were evaluated in early and late-
relapsing tumors in a series of 73 primary breast cancers and their corresponding 
metastases. The expression levels were compared between primary tumors and 
metastases, between the different groups according to the time of relapse after 
initial treatment, and with clinicopathological parameters, in order to analyze their 
putative roles in breast cancer progression.
The primary tumors belonged to the most common histological types of 
breast cancers: 55 ductal and 17 lobular adenocarcinomas, and additionally, one 
mucinous carcinoma.  There was no difference in the distribution of the tumor 
types between the early and late relapsing tumors. All corresponding metastases 
were morphologically similar to their primary counterparts. The clinicopathological 
parameters are presented in Materials and methods, Table 7. 
STUDY I
STANNIOCALCINS AND ER
Both STC-1 (Fig. 5) and STC-2 expression were elevated in late-relapsing tumors, 
especially in the recurrences. The mean frequency of positively stained tumor cells 
for	STC-1	showed	a	non-significant	tendency	to	higher	initial	expression	in	the	late	
recurring tumors compared to the early relapsing ones. The mean frequency of 
STC-1 stained tumor cells was 28% in primary cancers with contemporary or early 
recurrence (Group 1, Table 9). In the primary tumors of Group 2 (recurrence at 
5–10 years after primary surgery) the frequency was 31%, and in the latest relapsing 
tumors (Group 3) the frequency was 39% (Table 9). A more strongly increasing 
tendency of STC-1 expression was seen in the recurrent/metastatic tumors. The 
STC-1 positivity was 25% in Group 1, 53% in Group 2 and 71% in Group 3 (Table 9). 
STC-2 displayed a similar tendency of higher expression in late relapsing tumors 
than in the early relapsing ones. The mean frequency of STC-2 positively stained 
tumor cells was 3% in the primary tumors of Group 1, 13% in Group 2 and 17% 
in Group 3 (Table 9). In the recurrent/metastatic tumors the STC-2 frequency of 
positive tumor cells was 3% in Group 1, 26% in Group 2 and 58% in Group 3, the 
latest relapsing tumors (Table 9). 
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In the late-relapsing tumors (Groups 2 and 3), the frequency of positively stained 
cells	for	STC-1	and	STC-2	was	significantly	higher	in	the	recurrent	tumors	than	in	
their primary counterparts (p=.0012, p=.0017 for STC1 and p=.004 and p=.0001 
for STC-2, respectively) (Table 9). 
Stanniocalcins were not associated with ER expression in the primary cancers, 
but STC-1 was associated with ER in the recurrent/metastatic tumors (p=.019) 
(Table 12).
ER
The	frequency	of	ER-positive	(Fig.	6)	tumor	cells	did	not	significantly	vary	between	
the three groups, regarding the times of recurrence of the primary tumors. In the 
primary tumors, the ER mean expression was 30% in Group 1, 29% in Group 2 
and 24% in Group 3. In the recurrent/metastatic tumors the tendency was to an 
increased frequency of ER-positive stained tumor cells in the later relapsed tumors 
(30% in Group 1, 34% in Group 2 and 46% in Group 3) (Table 9). In the recurrences 
of the latest relapsing tumors (Group 3) the frequency of ER- positive tumor cells 
was		significantly	higher	compared	to	the	corresponding	primary	tumors		(p=.019) 
(Table 9). 
Fig. 5  STC-1 staining in a metastatic 
breast cancer of the latest 
relapsing tumors (Group 3)
Fig. 6 ER staining in a metastatic 
breast cancer of the latest 
relapsing tumors (Group 3)
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STUDY II
MASPIN, BCL-2, P53 
Maspin
In this study the cytoplasmic and nuclear maspin were separately evaluated. The 
cytoplasmic maspin expression (Fig. 7) was higher in the early relapsing tumors 
than in the late relapsing ones (Table 9) The mean proportion of positively stained 
tumor cells for cytoplasmic maspin was 19% in the primary cancers of the early 
relapsing  tumors of Group 1, 9% in Group 2 and 4% in the latest relapsing tumors 
Group 3.  The corresponding values in the recurrent/metastatic tumors were 23% 
in Group 1, 9% in Group 2 and only 1% in the latest tumor Group 3 (Table 9). 
Cytoplasmic	maspin	expression	varied	significantly	between	the	groups,	both	in	the	
primary cancers and in the recurrent/metastatic tumors when tested by Kruscall-
Wallis test (p=.019 in primary tumors and p=.023 in the recurrences) (Table 10). 
When tested by Mann-Whitney U-test,	there	was	a	significantly	higher	expression	
of cytoplasmic maspin in the early relapsing primary tumors of Group 1 than in the 
later relapsing tumors of Group 2 (p=.009) (Table 11). In the recurrent/metastatic 
tumors, the expression of cytoplasmic maspin tended to be higher in the early 
relapsing tumors in Group 1 compared to the latest relapsing tumors in Group 3 
(p=.010, Mann-Whitney U-test) (Table 11). The mean frequency of cytoplasmic 
maspin	expression	did	not	differ	significantly	between	the	primary	tumors	and	
their corresponding metastases (Table 9). 
	Nuclear	maspin	expression	was	significantly	higher	in	the	primary	cancers	of	the	
early relapsing tumors of Group 3, than in the corresponding recurrent/metastatic 
tumors (p=.033) (Table 9). Cytoplasmic maspin positivity correlated with the p53 
positivity both in the primary tumors and in the recurrences (p=004 in primary 
and p=.042 in the recurrent/metastatic tumors) (Table 12). 
Bcl-2
In contrast to the expression levels of cytoplasmic maspin, the levels of Bcl-2 staining 
(Fig.	8)	were	significantly	higher	in	late-relapsing	cancers,	both	primary	cancers	
and the recurrent/metastatic tumors, than in the early relapsing tumors (Table 9). 
The mean frequency of positively staining tumor cells for Bcl-2 was 25% in primary 
tumors of the early relapsing cancers of Group1, 37% in Group 2 and 55% in the 
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latest relapsing tumors of Group 3 (Table 9). In the recurrent/metastatic tumors, 
the mean expression of Bcl-2 was 11% in Group 1, 31% in Group 2 and 40% in the 
latest	relapsing	tumors	of	Group	3	(Table	9).		There	was	significantly	more	Bcl-2	
positivity in the recurrent cancers of the latest relapsing tumors of Group 3 compared 
to the recurrent tumors of early relapsing tumors of Group 1, when tested by the 
Kruscall-Wallis test (p=.005) (Table 10) and the Mann-Whitney U-test (p=.001) 
(Table 11). 
Bcl-2	positivity	correlated	significantly	with	ER	positivity,	in	both	primary	tumors	
(p=.007) and the recurrences (p=.0001) and with axillary node negativity in primary 
tumors (p=.004) (Table 12).  
p53 
The mean frequency of p53 positive (Fig. 9) stained tumor cells was higher in the 
early relapsing tumors than in the late relapsing ones, both in the primary cancers 
and in the recurrences (Table 9). The mean positivity of p53 was 25% in the primary 
Fig. 7  Maspin staining in an early-relapsing 
primary tumor (Group 1)
Fig. 8  Bcl-2 staining in a  primary tumor of the 
latest relapsing tumors (Group 3)
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tumors of the early relapsing cancers of Group 1, 19% in Group 2 and 5% in the latest 
relapsing tumors of Group 3 (Table 9).  The corresponding values in the recurrent/
metastatic tumors were 28% in Group 1, 12% in Group 2 and only 4% in the latest 
relapsing	tumors	of	Group	3	(Table	9).	p53	expression	did	not	differ	significantly	
between the primary tumors and the corresponding recurrences/metastases (Table 
9).		The	mean	P53	positivity	was	significantly	higher	in	the	recurrences	of	the	early	
relapsing tumor Group 1 than in the latest relapsing tumors of Group 3 when tested 
with the Kruskall-Wallis  test (p=.006) (Table 10) and the Mann-Whitney U-test 
(p=.002) (Table 11).  
p53 negativity was associated with cytoplasmic maspin negativity both in primary 
tumors (p=.004) and in the recurrent/metastatic tumors (p=.042) (Table 12). 
p53 positivity also associated with ER negativity in recurrent/metastatic tumors 
(p=.008) (Table 12).
STUDY III 
BMI-1, C-MYC AND  SNAI1 
Bmi-1
The mean frequency of Bmi-1 positive (Fig. 10) stained tumor cells was 30% in the 
primary tumors of the early relapsing cancers (Group 1), 32% in Group 2 and 42% 
in the latest relapsing tumors of Group 3 (Table 9). The corresponding values in 
Fig. 9 p53 staining in an early 
relapsing primary tumor 
(Group 1)
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recurrent/metastatic tumors were 53% in Group 1, 37% in Group 2 and 65% in Group 
3.	The	mean	Bmi-1	positivity	was	significantly	higher	in	the	tumor	recurrences/
metastases than in the primary cancers, both in the early recurring tumors of  Group 
1, and in the latest recurring tumors of  Group 3 (p=.004 and p=.019, respectively) 
(Table 9).  The mean expression of Bmi-1 in the primary tumors did not differ 
between the three groups (Table 10). In the recurrent/metastatic tumors there was 
significantly	more	Bmi-1	expression	in	the	latest	relapsing	tumor	Group	3		than	
in Group 2  (p=.007; Kruskal-Wallis test, Table 10, and p=.003; Mann-Whitney 
U test, Table 11).
c-myc
The mean nuclear positivity of c-myc in primary tumors was 12% in Group 1, 2% 
in Group 2 and 16% in Group 3 (Table 9). The corresponding ratios in recurrence 
were 5% in Group 1, 9% in Group 2 and 19% in Group 3. The mean cytoplasmic 
c-myc positivity in primary tumors was 18% in Group 1, 11% in Group 2 and 7% 
in Group 3 and the corresponding ratios in recurrences were 12% in Group 1, 25% 
in Group 2 and 8% in Group 3 (Table 9). The nuclear or cytoplasmic expression 
of	c-myc	did	not	differ	significantly	between	the	groups,	neither	 in	the	primary	
tumors nor in the recurrences.
There	was	significantly	more	both	nuclear	and	cytoplasmic	c-myc	positivity	in	
the metastases of Group 2 than in the corresponding primary tumors (p=.013 for 
nuclear c-myc and p=.033 for cytoplasmic c-myc) (Table 9). Nuclear c-myc in the 
primary	tumors	associated	significantly	with	axillary	node	positivity	(p=021) (Table 
12). Cytoplasmic c-myc positivity in the primary tumors associated with high Snail 
expression (p=.002 for invasive front Snail and p=.011 for central Snail) (Table 12).
Fig. 10 Bmi-1 staining in a breast 
cancer metastasis of the latest 
metastasizing tumor group 
(Group 3). 
66
JOENSUU – Tumor Dormancy In Breast Cancer 
Snail 
The mean Snail positivity was evaluated separately in the invasive front and central 
area of the tumors. Sometimes there was greater expression of Snail in invasive 
front than in central areas of the tumors, but generally the mean Snail positivity 
was equally high in the tumors – both in the primary cancers (range 85.5 – 88.7) 
and in the recurrences/metastases (range 78.5 – 91.3) (Table 9). Snail expression 
did	not	differ	significantly	between	the	primary	tumors	and	their	metastases	 in	
any of the three groups (Table 9), nor did the three groups differ statistically in 
Snail expression. High Snail expression was associated with cytoplasmic c-myc 
positivity in the primary tumors, as mentioned in the preceding section on c-myc. 
High invasive front and central Snail positivity was associated with Bmi- positivity 
in the recurrent/metastatic tumors (p=.0001 for invasive front Snail and p=.009 
for central Snail (Table 12).
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Table 9. Differences in the mean proportion of positive stainined tumor cells for STC-1, STC-2 and 
ER  (%; range, 0–100%) between the primary tumors and their corresponding recurrent/
metastatic tumors. The patients are divided in to Groups 1, 2 and 3 according to the time of 
relapse after primary diagnosis. Paired samples t- test was used. Values are shown as % mean 
(SD deviation).
Group n Primary Recurrent/metastatic   p
STC-1
1 19 27.7 (32.3) 25.2 (31.3) .66
2 35 30.8 (27.2) 53.3 (33.7) .0012*
3 18 39.2 (32.7) 70.5 (32.7) .0017*
STC-2
1 19 2.5 (3.3) 3.3 (5.4) .54
2 35 13.2 (19.6) 26.1 (26.2) .004*
3 18 17.4 (16.3) 57.5 (36.9) .0001*
ER
1 19 30.3 (35.4) 30 (40.6) .95
2 35 29.2 (37.5) 34.4 (38.7) .38
3 18 24.1 (35.5) 45.6 (40.2) .019*
Maspin cytoplasmic
1 19 18.8 (23.6) 23.2 (30.2) .409
2 34 8.5 (23.1) 9 (22.1) .860
3 20 4.2 (9.3) 1 (3.3) .149
Maspin nuclear
1 19 4.8 (8.6) 8.1 (17.4) .305
2 34 2.8 (10.8) 3 (6.9) .908
3 20 9.7 (17.3) 1.6 (4) .033*
Bcl-2
1 19 25.4 (33.1) 10.5 (20) .037*
2 34 37 (35.8) 30.8 (36.5) .098
3 20 54.8 (40.2) 40 (39.9) .408
p53
1 19 24.5 (35.2) 27.5 (34.8) .621
2 34 18.8 (32.5) 11.9 (25.3) .098
3 20 5.3 (20.6) 4.2 (16.1) .408
Bmi-1
1 19 30.1 (27.3) 53 (28.4) .004*
2 33 32 (35.7) 37 (33.4) .466
3 21 41.9 (36.9) 64.9 (25.1) .019*
c-myc nuclear
1 19 11.5 (17.9) 4.7 (9.9) .168
2 33 2.3 (4.1) 8.6 (13.9) .013*
3 21 16.0 (28.0) 18.9 (31.6) .783
c-myc cytoplasmic
1 19 17.9 (25.8) 12.4 (22.1) .306
2 33 10.6 (20.9) 25.0 (31.6) .033*
3 21 6.8 (15.9) 18.9 (31.6) .897
Snail frontal
1 19 88.7 (17.5) 93.3 (8.2) .280
2 33 85.5 (23.7) 88.5 (21.5) .497
3 21 88.1 (21.7) 88.5 (21.5) .479
Snail central
1 19 85.7 (14.0) 90.3 (10.7) .246
2 33 77.0 (30.2) 78.5 (26.3) .801
3 21 79.0 (30.5) 91.3 (10.8) .120
Note. Group 1 (n= 19) includes patients with recurrence or metastasis detected within 2 years of diagnosis. Group 2 
(n=35) and 3 (n=18) include patients with recurrence or metastasis detected between 5-10 and after 10 years 
of follow-up, respectively.
* statistically significant 
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Table 10.  Differences in mean proportion of positively stained tumor cells between the 3 groups of 73 
breast cancers,in primary tumors and in their recurrent/metastatic tumors. The patients are 
divided into 3 groups, according to the time of relapse after primary diagnosis. The Kruskal-
Wallis test was used.
Staining Group n Mean rank p
Maspin cytoplasmic
Primary 1  19 47.2 .019*
2  34 32.2
3  20 35.4
Recurrent/metastatic 1  19 46.1 .023*
2  34 35.3
3  20 31.3
Bcl-2
Primary 1  19 29.9 .061
2  34 35.9
3  20 45.5
Recurrent/metastatic 1  19 25.6 .005*
2  34 37.6
3  20 46.8
p53
Primary 1  19 40.6 .089
2  34 39.4
3  20 29.5
Recurrence/metastatic 1  19 46 .006*
2  34 36.1
3  20 27.7
Bmi-1
Primary 1 19 37 .397
2 33 38.8
3 21 41.8
Recurrent/metastatic 1 19 39.7
2 33 28.9
3 21 47.2 .007*
Note: Group 1 includes patients with a recurrence or metastasis detected within 2 years of diagnosis. Groups 2 and 3 
include patients with a recurrence or metastasis detected at 5–10 years, or after 10 years of follow-up, respectively.
* statistically significant
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Table 11. Staining differences of cytoplasmic maspin, Bcl-2, p53 and Bm1-1 between 2 groups. The 
patients are divided into 3 groups, according to the time of relapse after primary diagnosis. 
Mann-Whitney U test was applied, if Kruskal-Wallis test showed a significant difference 
between the 3 groups. P value was considered statistically significant*, if it was < 0.0167 
(<0.05/3).
U Z p
Maspin cytoplasmic
Primary Group 1 vs group 2 198 -2.626 .009*
Group 1 vs group 3 121.5 -2.048 .041
Group 2 vs group 3 303 -.805 .421
Recurrent/metastatic Group 1 vs group 2 229.5 -2.022 .043
Group 1 vs group 3 111.5 -2.571 .010
Group 2 vs group 3 304.5 -.848 .396
Bcl-2
Primary Group 1 vs group 2 215.5 -2.141 .032
Group 1 vs group 3   81 -3.200 .001*
Group 2 vs group 3 252.5 -1.600 .110
p53
Recurrent/metastatic Group 1 vs group 2 231 -1.876 .061
Group 1 vs group 3   92 -3.055 .002*
Group 2 vs group 3 244 -1.889 .059
Bmi-1
Recurrent/metastatic Group 1 vs group 2 215.0 -1.880 .060
Group 2 vs group 3 178.0 -2.996 .003*
Group 1 vs group 3 153.0 -1.266 .206
Note. Group 1 (n=19) includes patients with a recurrence or metastasis detected within 2 years of diagnosis. Groups 2 
(n=34, for Bmi-1 n=33) and 3 (n=20, for Bmi-1 n=21) include patients with a recurrence or metastasis detected 
at 5–10 years, or after 10 years of follow-up, respectively.
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Table 12. Relationship between cytoplasmic maspin, Bcl-2, p53, ER, c-myc, Snail and clinicopathological 
parameters in 73 primary breast cancers and recurrent/metastatic tumors. Categorical  
Pearson’s Chi-square test was used. Only statistically significant results are shown.
Primary 
Maspin cytoplasmic 
negative n (%)
Maspin cytoplasmic 
positive n (%)
p
p53 neg 44 (81) 9 (47)
p53 pos 10 (19) 10 (53) .004
Bcl-2 
negative n (%)
Bcl-2 
positive n (%)
ER neg 21 (78) 21 (46)
ER pos 6 (2) 25 (54) .007
Node neg 7 (26) 28 (61)
Node pos 20 (74) 18 (39) .004
Bmi-1 
negative n (%)
Bmi-1 
positive n (%)
ER negative 19 (46) 22 (54)
ER positive 6 (19) 26 (81) .014
Nuclear c-myc 
negative n (%)
Nuclear c-myc 
positive n (%)
Node negative 31 (91) 3 (9)
Node positive 27 (69) 12 (31) .021
Cytoplasmic c-myc 
negative n (%)
Cytoplasmic c-myc 
positive n (%)
Snail invasive front low 13 (100) 0
Snail invasive front high 33 (55) 27 (45) .002
Snail invasive front low 18 (86) 3 (14)
Snail invasive front high 28 (54) 24 (46) .011
Recurrent/metastatic
STC-1 
negative n (%)
STC-1
positive n (%)
ER negative 11 (38) 18 (62)
ER positive 6 (14) 37 (86) .019
Maspin cytoplasmic 
negative n (%)
Maspin cytoplasmic 
positive n (%)
p53 negative 43 (78) 9 (53)
p53 positive 12 (8) 8 (47) .042
Bcl-2 
negative n (%)
Bcl-2 
positive n (%)
ER negative 23 (59) 6 (18)
ER positive 16 (41) 28 (82) .0001
p53 
negative n (%)
p53 
positive n (%)
ER negative 16 (31) 13 (65)
ER positive 36 (69) 7 (35) .008
Bmi-1 negative n (%) Bmi-1 positive n (%)
ER negative 10 (26) 28 (74)
ER positive 1 (3) 34 (97) .005
Snail invasive front low 4 (67) 2 (33)
Snail invasive front high 7 (10) 60 (90) .0001
Snail invasive front low 5 (39) 8 (62)
Snail invasive front high 11 (18) 49 (82) .009
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STUDY IV
ER, PR, HER2, KI67, CK5, THE CLINICOPATHOLOGICAL PARAMETERS AND THE 
IHC DEFINED APPROXIMATIONS TO THE INTRINSIC GENETICALLY 
DEFINED BREAST CANCER SUBTYPES 
Clinicopathological parameters 
The  results of the univariate analysis of clinicopathological parameters are shown in 
Table 13. Axillary node positivity was associated with early tumor relapse (p=.006). 
High tumor grade and tumor size greater than 20 mm was also associated with 
early tumor recurrence (p=.008 for tumor grade and p=.021 for tumor size). No 
significant	differences	were	seen	between	the	groups	in	regard	to	age	or	histological	
type	of	tumor.	In	multivariate	analysis,	increasing	tumor	size	significantly	enhanced	
the risk of early tumor relapse (OR 1.07, CI 1.01 – 1.12) (Table 16). An increase of 
1 mm in tumor size thus increased the risk of early breast cancer relapse by 7%.
ER
ER positivity (Fig. 6) in the primary tumors in this cohort of 72 tumors was 68%. 
The positivity between primary and recurring tumors changed most in the early 
relapsing tumors of Group 1, where 3 ER-positive tumors became ER-negative in 
the recurrences (15% decrease) (Table 14). ER positivity was associated with late 
tumor relapse (p=0.47)	(Table	13).	In	multivariate	analysis,	ER	was	not	a	significant	
risk factor for late relapse. ER positivity was associated with axillary node negativity 
(p=.014), low grade (p=.024), and HER2 negativity (p=.046) in the primary tumors, 
data not shown. 
PR
There	were	significantly	more	PR-positive	(Fig,	13)	primary	tumors	(38%)	compared	
to the recurrent cancers (24%) in the entire tumor set (n=72, p=.005) (Table 14). 
A decrease in PR positivity was also seen in the recurrent/metastatic tumors of all 
three	groups.	The	decrease	in	the	number	of	PR-positive	tumors	was	most	significant	
(31%) in the latest relapsing tumors of Group 3 (p=.030) (Table 14). There were 
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no	significant	differences	in	PR	expression	between	the	groups.	PR	positivity	 in	
the primary tumors was associated with node negativity (p=.017), data not shown. 
HER2
There was a high concordance (97%) of HER2 overexpression (Fig. 11) measured by 
both IHC and CISH between the primary tumors and the corresponding metastases 
in all three groups, according to the time after primary detection of the cancers 
(Table 14). There were 15 (21%) HER2-positive primary and 15 (21%) positive 
recurrent/metastatic tumors in the whole tumor set (Table 14). Only three pairs with 
discordant HER2 status were found in the entire tumor material of paired primary 
and metastatic tumors. One primary tumor, belonging to the early relapsing Group 1, 
was HER2-positive by IHC and CISH, but its metastasis was CISH-negative. Another 
case of discordance was noted in Group 1: the primary tumor was HER2-positive 
by both IHC and CISH, and the recurrent tumor was negative (1+) by IHC, but 
CISH-positive. In the third case of discordance, a primary tumor from Group 3 was 
negative for HER2 by both IHC and CISH, but the metastasis was positive by both 
IHC	and	CISH.	One	tumor	of	all	CISH-positive	cases	displayed	low	amplification.	
When tested with the chromosome 17 centromere probe, this case showed an average 
HER2/Chr17	ratio	over	2,	and	turned	out	to	be	HER2	gene	amplified.
HER2	over-expression	signified	early	 tumor	relapse	(p=.003) (Table 13). In 
multivariate	analysis,	HER2	negativity	significantly	lowers	the	risk	of	early	tumor	
relapse (OR 0.19 95% CI 0.04–0.83) (Table 16) or inversely, HER2 positivity 
increases the risk of early tumor relapse by 1/0.19 = 5.3. HER2 negativity was 
associated with node negativity (p=.018), low tumor grade (p=.021), and Ki67 
negativity (p=.008) in the primary tumors, data not shown. 
Fig. 11 HER2 over-expression in an early relapsing breast cancer of Group 1, a (IHC), b (CISH)
a b
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Ki67
The expression of Ki67 (Fig. 12) was associated with early tumor relapse (p=.012) 
(Table 13) in univariate analysis, but not in the multivariate test. The positivity 
of Ki67 (>14% positively stained tumor cells) declined gradually from the early 
relapsing tumors (Group 1), toward the latest relapsing tumors of Group 3 (Table 
14)  There were 68% primary Ki67 positive breast cancers in the early relapsing 
tumor Group 1, 42% in Group 2 and 21% in the latest relapsing tumors of Group 
3. The corresponding ratios in recurrent/metastatic tumors were 74% in Group 1, 
62%	in	Group	2	and	21%	in	Group	3.	There	were	significantly	more	Ki67-positive	
recurrent/metastatic cancers in the tumors of Group 2 (recurrences at 5–10 years) 
than in the corresponding primary tumors (p=.017) (Table 14).
Ki67 positivity was associated with axillary node positivity (p=.027), high grade 
(p=.0001), ductal histological type (p=.026), and HER2 positivity (p=.008) in the 
primary tumors, data not shown. 
CK5
In	the	whole	tumor	set	of	72	breast	cancers,	there	were	significantly	more	CK5-
positive (Fig. 13) primary cancers compared to the recurrent/metastatic tumors 
(31% and 11%, respectively, p=.0001) (Table 14). The expression of CK5 declined 
gradually from the early relapsing tumors toward the late relapsing ones. There 
were 58% CK5 positive tumors in Group 1, 24% in Group 2 and 16% in Group 3. 
The corresponding ratios in recurrences were 26% in Group 1, 9% in Group 2 and 
none	in	Group	3	(Table	14).	As	in	the	whole	tumor	set,	there	was	also	a	significant	
Fig. 12 Ki67 positive staining in a metastatic 
tumor of the early relapsing breast 
cancers (Group 1)
Fig. 13 CK 5 (red)/PR (brown) dual staining in 
early relapsing breast cancer (Group 1)
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loss of CK5 positivity in the recurrent tumors of the early relapsing cancers of Group 
1 (p=.010) (Table 14). 
In	 univariate	 analysis,	 CK5	 expression	 associated	 significantly	 with	 early	
tumor relapse (p=.009) (Table 13), but not in multivariate analysis. CK5 positivity 
correlated	significantly	with	metastases	to	the	axillary	lymph	nodes	(p=.025), high 
tumor grade (p=.0001), ductal histological type (p=.003), ER negativity (p=.029), 
and Ki67 positivity (p=.0001), data not shown.
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Table 13. Relationship of clinicopathological parameters, ER, PR, HER2, Ki67 and CK5 protein 
expression in primary tumors of 72 breast cancer patients. The patients are divided into 3 
groups, according to the time of relapse after primary diagnosis. Categorical  Pearson’s Chi-
square test was used. 
Group Node negative n (%) Node positive n (%) p
1 3 (16) 18 (84)
2 20 (59) 14 (41)
3 11 (58) 8 (42) .006*
Grade 1      Grade 2 Grade 3
1 0 8 (42) 11 (58)
2 5 (15) 19 (56) 10 (29)
3 3 (16) 15 (79) 1 (5) .008*
size < 20 mm size > 20 mm
1 3 (16) 16 (84)
2 16 (47) 18 (53)
3 11 (58) 8 (42) .021*
ER negative ER positive
1 10 (53) 9 (47)
2 10 (29) 24 (71)
3 3 (16) 16 (84) .047*
PR negative PR positive
1 13 (68) 6 (32)
2 15 (44) 19 (56)
3 6 (32) 13 (68) .066
HER2 negative HER2 positive
1 10 (53) 9 (47)
2 29 (85) 5 (15)
3 18 (95) 1 (5) .003*
Ki67 negative Ki67 positive
1 6 (32) 13 (68)
2 20 (59) 14 (41)
3 15 (79) 4 (21) .012*
CK5 negative CK5 positive
1 8 (42) 11 (58)
2 26 (77) 8 (24)
3 16 (84) 3 (16) .009*
Note: Group 1 (n=19) includes patients with a recurrence or metastasis detected within 2 years of diagnosis. Groups 
2 (n=34) and 3 (n=19) include patients with a recurrence or metastasis detected at 5–10 years, or after 10 years 
of follow-up, respectively.
* statistically significant
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Table 14. Expression of CK5, ER, PR, HER2 and Ki67 as compared in primary and metastatic tumors 
of 72 breast cancer patients. The patients are divided into 3 groups, according to the time of 
relapse after primary diagnosis. Paired samples t-test was used.
Primary 
positive n (%)
Recurrent/metastatic
positive n (%)
p
ER
All cases n=72 49 (68) 47 (65) .596
Group
1 9 (47) 6 (32) .083
2 24 (71) 25 (74) .711
3 16 (84)       16 (84)         1.000
PR
All cases n=72 38 (53)           . 24 (33) .005*
Group
1 6 (32) 4 (21) .331
2 19 (56) 13 (38) .110
3 13 (68) 7 (37) .030*
HER2
All cases n=72 15 (21)         15 (21)         1.000
Group
1 9 (47)          8 (42)              .331
2 5 (15)            5 (15)             1.000
3 1 (5) 2 (11) .331
Ki67
All cases n=72 31 (43) 39 (54) .059
Group
1 13 (68) 14 (74) .667
2 14 (42) 21 (62) .017*
3 4 (21) 4 (21) 1.000
CK5
All cases n=72 22(31) 8 (11) .0001*
Group
1 11(58) 5 (26) .010*
2 8(24)              .43 3 (9)                .058
3 3(16)              .37 0 .083
Note: Group 1 (n=19) includes patients with a recurrence or metastasis detected within 2 years of diagnosis. Groups 
2 (n=34) and 3 (n=19) include patients with a recurrence or metastasis detected at 5–10 years, or after 10 years 
of follow-up, respectively. 
* statistically significant
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Relationship of the IHC surrogates to the intrinsic genetical defined subtypes, 
luminal A (ER or PR+HER2-), luminal B (ER or PR+HER2+), HER2 over-
expressing (ER-PR-HER2+), triple-negative (ER-PR-HER2-), basal-like 
(ER-PR-HER2-CK5+), unclassified (ER-PR-HER2-CK-) and luminobasal 
(ER or PR+CK+) to early and late recurrence of tumors.
There were altogether 35 (49 %) primary tumors of luminal A (ER or PR+HER2-) 
type	 and	 this	 subtype	 signified	 late	 tumor	 recurrence	 (p=.0001,	 Table	 15)	 in	
univariate analysis. In multivariate analysis, the non-luminal A phenotype of tumors 
increased	significantly	the	risk	of	early	tumor	relapse	(OR	3.26	95%	CI	1.01–10.59)	
(Table	16),	i.e.	the	subtype	luminal	A	of	tumors	with	this	changing	coefficient	of	
0.3067 (1/3.26=0.3067) lowers the risk 100*(1–0.3067) = 69.33%.  
There were only 2 (11%) luminal A type tumors in the early relapsing tumors 
of Group 1, 20 (59%) in Group 2  and 13 (68%) in  the latest relapsing tumors of 
Group 3 (Table 15).  The other subtypes were rare, and they mostly represented early 
relapsing	tumors,	but	there	were	no	significant	differences.	There	were	only	4	(11	%)	
luminal B type primary tumors in the whole tumor set,  2 (11%) in the early relapsing 
tumor Group1 , 2 (6%) in Group 2 and none in the latest recurring tumor group 
(Group 3) (Table 15).  There were 8 HER2 over-expressing (ER-PR-HER2+) type 
primary tumors, 5 (26%) in the early relapsing tumors of Group 1, 2 (6%) in Group 
2 and 1 (5%) in the latest relapsing tumors of Group 3. There were 14 luminobasal 
type of cancers, 6 (32%) in Group 1, 5 (15%) in Group 2 and 3 (16%) in Group 3. 
From the all 7 basal-like tumors 4 (21%) were in Group 1, 3 (9%) in Group 2 and 
none	in	Group	3.	There	were	4	non-classified	types	of	tumors,	none	in	Group	1,	2	
(6%) in Group 2 and 2 (11%) in Group 3. There  were 11 primary triple-negative 
type of tumors, 4 (21%) in Group 1, 5 (15%) in Group 2 and 2 (11%) in Group 3.
The triple-negative CK5 positive, basal-like tumors tended to associate with 
early tumor relapse (p=.055, Table 15). A total of 11 triple-negative pimary tumors 
occurred in the whole tumor set, 4 (21%) in the early relapsing tumors of Group 
1, 5 (15%) in tumor Group 2 (recurrence after 5 years) and 2 (11%) in the latest 
relapsing tumor Group 3.  The 4 triple-negative tumors in the early relapsing tumors 
(Group 1) were all CK5-positive, whereas the two triple-negative tumors in the latest 
recurring tumors (Group 3) were all CK5-negative (Table 15). 
Ki67 positivity associated with early tumor relapse in luminal B phenotype of 
tumors but not in luminal A type of cancers (p=.0001 in luminal A and p=.364 in 
luminal B type, data not shown).
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Table 15. Distribution of seven subtypes of tumors defined by IHC, in primary tumors of 72  breast 
cancer patients. The patients are divided into 3 groups, according to the time of relapse after 
primary diagnosis. Categorical Pearson’s Chi-square test was used.
Group Luminal A n (%) all others n (%) p
1 2 (11) 17 (90)
2 20 (59) 14 (41)
3 13 (68) 6 (32) .0001*
Luminal B all others
1 2 (11) 17 (90)
2 2 (6) 32 (94)
3 0 19 (100) .364
HER2 overexpressing all others
1 5 (26) 14 (74)
2 2 (6) 32 (94)
3 1 (5) 18 (95) .049*
Luminobasal all others
1 6 (32) 13 (68)
2 5 (15) 29 (85)
3 3 (16) 16 (84) .296
Basal-like all others
1 4 (21) 15 (79)
2 3 (9) 31 (91)
3 0 19 (100) .088
Non-classified all others
1 0 19 (100)
2 2 (6) 32 (94)
3 2 (11) 17 (90) .364
Triple-negative all others
1 4 (21) 15 (79)
2 5 (15) 29 (85)
3 2 (11) 17 (90) .660
Triple-negative CK5+ Triple-negative CK5-
1 4 (100) 0
2 3 (60) 2 (40)
3 0 2 (100) .055
IHC subtypes: Luminal A (ER or PR+HER2-), Luminal B (ERorPR+HER2+), HER2 overexpressing (ER-PR-HER2+), Basal-
like (ER-PR-HER2-CK5+), Luminobasal (ERorPR+CK5+), Non-classified (ER-PR-HER2-CK5-), Triple-negative CK5 
positive (ER-PR-HER2-CK5+).
Basal-like (ER-PR-HER2-CK5+) = Triple negative CK5+
Non-classified (ER-PR-HER2-CK5-) = Triple negative CK5-
Note. Group 1 (n=19) includes patients with a recurrence or metastasis detected within 2 years of diagnosis. Groups 
2 (n=34) and 3 (n=19) include patients with a recurrence or metastasis detected at 5–10 years, or after 10 years 
of follow-up, respectively.
* statistically significant
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Table 16.  Dependence of the time of tumor recurrence on different factors. Model 1 includes 
clinicopathological parameters and HER2, ER, CK5, Ki67. Model 2 includes the 
clinicopathological parameters and the subgroups luminal A and HER2 overexpressing, 
defined by IHC. The regression ordinal test was used.
Model 1 Variable Wald Sig. OR 95% Confidence interval
size (2mm–90mm) 0.011 1.07 1.02   –   1.13
HER2-negative 0.027 0.19 0.04   –   0.83
ER-negaative 0.228 2.03 0.64   –   6.41
CK5-negative 0.146 0.35 0.09   –   0.69
Ki67-negative 0.344 0.53 0.15   –   1.96
Node-negative 0.431 1.64 0.48   –   5.60
Grade  1 0.647 0.62 0.08   –   4.77
Grade  2 0.799 0.83 0.19   –   3.58
Model 2 Variable Wald Sig. OR 95% Confidence interval
size (2mm–90mm) 0.013 1.07 1.01   –   1.12
Non-luminal A 0.049 3.26 1.01   –   10.59
Non-HER2-overexpressing 0.211 0.34 0.06   –   1.85
Node-negative 0.593 1.39 0.41   –   4.67
Grade 1 0.153 0.26 0.04   –   1.65
Grade 2 0.277 0.47 0.12   –   1.84
Note: IHC subtypes: luminal A(ERorPR+HER2-), HER2 overexpressing(ER-PR-HER+).
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DISCUSSION
This summary is based on four studies, in which the expression of different proteins 
is described in a series of 73 primary breast cancers and their corresponding 
recurrences. 19 of the cancers were early relapsing tumors and 53 late recurring 
ones (after 5 or 10 years). Immunoexpressing levels of proteins were compared 
between the primary tumors and their metastases, as well as between early and 
late recurring cancers, and also with clinicopathological parameters, in order to 
analyze their putative role in breast cancer progression. 
STUDY IV
In Study IV, the established markers guiding breast cancer treatment after surgery of 
the primary tumor, i.e., ER, PR, HER2, Ki67, together with the basal-like cytokeratin 
CK5, were evaluated. The results were analysed with the clinicopathological 
parameters and the IHC surrogates of the intrinsic genetically defined subgroups 
of breast cancers, luminal A (ERorPR+HER2-), luminal B (ErorPR+HER+), 
HER2 over-expressing (ER-PR-HER2+), triple-negative (ER-PR-HER2-), basal-
like, (ER-PR-HER-CK5+), non-classified (ER-PR-HER2-CK5-) and luminobasal 
(ERorPR+CK5+). 
CLINICOPATHOLOGICAL PARAMETERS
The well known parameters for poor outcome in breast cancer, i.e., axillary node 
positivity, high tumor grade, and tumor size (Elston et al.1982) were associated 
with early tumor recurrence in univariate analysis. In multivariate analysis, tumor 
size was the most significant risk factor for early recurrence. Galea et al. (1982) 
have also shown tumor size to be a significant risk factor for poor prognosis in 
breast cancer patients in multivariate analysis.  Excellent estimates for breast cancer 
growth rates, based on cancer incidence and tumor measurements from almost 
400,000 women who were 50–69 years of age, have been calculated from Norwegian 
mammography screening studies (Weedon-Fekjaer et al. 2008). The 5% fastest 
growing tumors took 1.2 months to grow from 10 to 20 mm in diameter, whereas 
the 5% slowest growing tumors needed more than 6.3 years. Assuming constant 
exponential or logistic growth for small tumors (i.e., without a dormancy period 
or retarded growth), the fast growing tumors reached a size of 10 mm within one 
year, and the slow growing tumors in more than 50 years. For the 5% fast growing 
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cancers, a period of dormancy is very likely when no metastasis is found within 
two years after diagnosis. In the second group, dormancy is highly unlikely, even 
when it is assumed that the dissemination of tumor cells and initiation of metastasis 
occurred shortly after malignant transformation. Therefore, metastasis dormancy 
may occur in cases of early relapse, although absent in very late recurrences. This 
individual variation may be one reason why it is not possible to deduce the state of 
dormancy from clinical studies or epidemiological data, and has led to conflicting 
results (Klein 2011, Demiceli  2001, Demiceli et al. 1996). 
ER AND PR
In this study, ER positivity was associated with very late tumor relapse, which 
is in accordance with previous reports (Hess et al. 2003, Brewster et al. 2008). 
The heterogeneity of ER expression within an individual tumor, between different 
tumors, and also between primary tumors and their metastases, is a well known 
phenomenon. 
The discordance of the receptor status between primary and metastatic breast 
cancers has been known for over 30 years (Brennan et al. 1979).  Such discordance 
in estrogen and progesterone receptors can occur in as many as 40% of breast 
cancers (Li et al. 1994, Kuukasjärvi et al. 1996).  
In my tumor material, there were 15% more ER-positive primary tumors 
compared to their metastases in the early relapsing cancers. In a study of 75 patients, 
Sari et al. demonstrated that 21% of ER-positive tumors did not express ER in their 
metastases and, in contrast, 15% of ER-negative primary tumors were positive in 
their metastases (Regitnig et al. 2004). In our study, only one (3%) primarily ER-
negative tumor had an ER-positive metastasis.  Hoefnagel et al. (2010) showed 
inversion of primary ER-positive tumors into negative metastases in 10.7 % and 
from negative into positive in 3.4% of their patients. The corresponding numbers 
in the study of Thomson et al. (2010) were 8% from positive into negative, and 
vice versa in 2.2% of their cases. 
Several studies have shown that in breast cancer late metastases mostly display 
higher ER and PR expression than do the primary cancer and early metastases 
(Spataro et al. 1992). 
The mechanism of ER in tumor dormancy is likely to be related to its role as 
a receptor of estrogen, which is the most potent breast cancer growth factor. By 
expressing functional ER, the cancer cells retain their receptor-mediated capability 
to connect with their ligand, the transcription and mitogen factor estrogen, and 
to maintain tumor proliferation and growth. ER may also act as a breast cancer 
survival factor. After a long period of silence in cancer manifestation after the primary 
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endocrine treatments, residual tumor cells are left with functional estrogen receptors. 
It may thus be possible that the cells can be reactivated by new hormonal influence. 
This study supports the conclusion of Brewster et al. (2008), patients with early-
stage breast cancer who are disease-free at 5 years after adjuvant systemic therapy 
(AST) have a substantially increased residual risk of recurrence. The findings in 
this study confirm that ER acts as a DTC and micrometastasis growth factor, and 
is a risk factor for a tumor to escape from dormancy. 
A positive estrogen receptor status in breast cancer is associated with a good 
response to hormonal therapy, a good prognosis, and a long disease-free and overall 
survival (Vollenweider et al. 1986). The additional prognostic and predictive value 
of the progesterone receptor has remained controversial. Liu et al. (2010) examined 
the value of PR for prognosis and response to tamoxifen in a population-based series 
of 4046 invasive early stage breast cancer patients. Survival analyses for both the 
whole cohort and the ER-positive cases that were given tamoxifen therapy showed 
that patients with PR-positive tumors had better breast cancer specific survival. 
Cui et al. (2003) demonstrated that IGF-I (insulin-like growth factor-1) inhibits 
progesterone receptor expression in breast cancer cells via the phosphatidylinositol 
3-kinase/akt/mammalian target of the rapamycin pathway. The authors suggested 
that low PR expression may indicate activated growth factor signalling in breast 
cancer cells, and therefore point to an aggressive tumor phenotype and resistance 
to hormonal therapy.
 PR expression may define a subpopulation of breast cancer patients who have 
a stronger dependence on hormone receptor-associated growth, and consequently 
a superior response to hormone therapy (Cui et al. 2005). 
In this study, PR positivity between metastases and primary tumors changed 
mostly in the latest relapsing tumors, where 6 out of 13 PR-positive tumors turned 
out to be negative in the metastases. The role of progesterone in early or late tumor 
recurrence in the present study remains unclear. It is possible that PR is more an 
ER-dependent factor than an individual factor in breast cancer progression. 
The change in hormone receptor status during tumor progression has also been 
demonstrated by Aktas et al. (2011), who compared hormone receptor expression 
of CTCs with the primary tumors of patients who had developed metastases. They 
showed that most of the CTCs were ER/PR-negative, despite the presence of an 
ER/PR-positive primary tumor. Another recent study compared the hormone 
receptor status between primary tumors and the CTCs, and showed that the most 
common CTC phenotype was triple-negative, followed by HER2+/ER-PR subtype 
and ERorPR-positive, while 95% of the corresponding primary tumors were ER- and 
PR-positive. Furthermore, before as well as after surgery, CTC phenotype generally 
remained identical, but could differ from that of the primary tumor (Banys et al. 
2011).
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HER2
As anticipated, HER2 over-expression was associated with early tumor recurrence, 
and it was highest in the early-relapsing tumors. HER2 over-expression was also 
associated with other poor prognostic factors, such as node positivity, high tumor 
grade, ER negativity, and high Ki67 expression. This is in agreement with earlier 
reports (Ross and Fletcher 1998). There was a high concordance of HER2 over-
expression between the primary tumors and the metastases. In the late-relapsing 
tumor group (metastasis after 10 years), one primarily HER2-negative tumor was 
found to over-express HER2 in metastasis. In contrast, Regitnig et al. (2004) 
detected HER2 over-expression de novo in 9.7% of distant breast cancer metastases 
at a late disease stage.  In the present study, HER2 positivity was a significant risk 
factor in multivariate analysis for early tumor recurrence. Because HER2 is a strong 
breast cancer growth factor, it promotes metastatic progression and escape from 
tumor dormancy (Pantel 2009). 
The impact of HER2 in predicting metastatic growth and escape from tumor 
dormancy was also shown by Hayashi et al. (2012), who demonstrated that patients 
with HER2-positive CTCs had a significantly shorter progression-free and overall 
survival than did patients without HER2-positive CTCs. They also noted that 24.2% 
of patients with HER2-negative primary tumors had HER2-positive CTCs during 
the study period (Hayashi et al. 2012). 
KI67
In this tumor material, Ki67 expression with a cut-off point of 14% clearly 
differentiated tumors into slowly progressing tumors and those progressing more 
aggressively. Ki67 expression denoted early-relapsing tumors and correlated linearly 
with tumor progression, since Ki67 positivity declined gradually from early-relapsing 
toward late-recurring tumors. Luminal A-type tumors were associated with low 
Ki67 expression, and Ki67 positivity was associated with late tumor recurrence in 
Luminal A type tumors, but not in luminal B type cancers. This is in agreement with 
Cheang et al. (2009), who described an immunopanel of ER, PR, HER2, and Ki67 
that can separate the Luminal A and B subtypes. As a proliferating marker, Ki67 
supports tumor growth and metastatic progression. It is a marker that supports 
escape from tumor dormancy, and Ki67 positivity in CTCs indicates that these 
tumor cells are non-dormant (Aguirre-Chiso 2007).
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CK5
The basal type cytokeratin CK5 expression correlated with poor prognostic features, 
such as early recurrence, axillary lymph node positivity, high tumor grade, Ki67 
positivity, and ER negativity in this tumor material. The results are in line with those 
of	Banerjee	et al. (2006) and Choccalingam et al. (2012), who also demonstrated 
that	basal-like	breast	cancer,	defined	by	basal	cytokeratin	expression,	correlated	
with a negative hormonal status and shorter disease-free intervals. 
In	this	study,	there	was	a	significant	loss	of	CK5	expression	in	the	metastases.	In	
contrast, Tot (2000) demonstrated a high concordance of CK5 positivity between 
primary breast cancers and their metastases, which seems to be explained with 
the medullary histological breast cancer type in their study differing to the ductal 
and lobular cancers in this tumor material. Su et al. (1996) described alterations 
in cytokeratin expression and partial loss of the normal regulation of cytokeratin 
expression during carcinogenesis and tumor progression. In normal mammary 
gland, a small number of cells that are positive for CK5 are located in the luminal 
compartment; they display morphological features of stem cells and have the capacity 
to differentiate towards either glandular or basal phenotype (Boecker and Buerger 
2003).	It	is	postulated	that	tumors	containing	a	sufficient	population	of	cancer	stem	
cells are capable of self-renewal and of forming new tumors.  CK5 can be regarded 
as a factor that supports tumor metastatic progression and escape from dormancy. 
RELATIONSHIP BETWEEN THE IHC SURROGATES TO THE INTRINCIC GENETICAL 
DEFINED BREAST CANCER SUBTYPES, LUMINAL A, LUMINAL B, HER2-
OVER-EXPRESSING, TRIPLE-NEGATIVE , BASAL-LIKE , UNCLASSIFIED  
AND LUMINOBASAL WITH EARLY AND LATE RECURRENCE OF TUMORS 
The	most	significant	and	well	known	factor	which	lowers	the	risk	of	early	tumor	
relapse in this study was the luminal A tumor type. The behavior of this tumor 
type	can	easily	be	seen	to	reflect	HER2	negativity,	low	Ki67	expression	and	slow	
proliferation	of	these	tumors,	as	well	as	the	endocrine	adjuvant	therapies	of	the	
patients after repression of their ER-positive tumors. 
 The luminal A subtype of tumors correlated with low Ki67 expression. This is in 
agreement with the study of Cheang et al. (2009), who described an immunopanel of 
ER, PR, HER2, and Ki67 that can segregate the luminal A and B subtypes. Luminal 
breast cancers with Ki67 levels of at least 14% had a worse prognosis for both cancer 
recurrence and death, compared with tumors whose Ki67 levels were below 14%.
In this study, CK5-positive ‘Triple-negative’ basal-like tumors associated with 
early tumor recurrence, which is in line with the results of Cheang et al. (2008). 
They showed that patients with CK5- positive triple-negative breast cancers had 
worse overall survival than the subgroup of CK5 negative triple-negative cancers. In 
this study there were 11 triple-negative primary tumors, of which 4 triple-negative 
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tumors belonged to early relapsing tumors and were all CK5-positive, whereas 
there was no CK5-positive triple-negative tumor among the latest relapsing tumors. 
STUDY I
STANNIOCALCINS
The	expression	of	both	STC-1	and	STC-2	was	significantly	elevated	in	late-recurring	
tumors, expecially in the metastases, indicating that the results were in agreement 
with the presumed roles of stanniocalcins in maintaining cell survival, and supporting 
tumor dormancy. Stanniocalcins have been found to act as survival factors. They 
confer cytoprotection against hypoxic and hypercalcemic stress, particularly in 
terminally differentiated normal cells with limited or absent proliferative capability 
(Serlachius et Andersson 2004). In addition to its various biological processes, 
STC-1 has been associated with angiogenesis (Kahn et al. 2000). The role of this 
gene	in	angiogenesis	is	not	known,	but	a	significant	increase	in	STC-1	mRNA	levels	
was shown in an in vitro experimental model of angiogenesis (Kahn et al. 2000). 
The role of stanniocalcins in angiogenesis may be related to their capability to 
respond to cellular hyperoxide, hypoxive and osmotic stress (Kahn et al. 2000, 
Zhang et al. 2000, Westberg et al. 2007).  The association of elevated expression of 
stanniocalcins in late relapsing tumors and correlation with favorable early outcome 
of the patients as well as tumor dormancy in this study is supported by Nguyen et 
al. (2009). They found that STC1 acts in a negative feedback loop in the prosurvival 
ERK1/2 signalling pathway during oxidative stress.
Contrary	to	the	stanniocalcins	in	fish,	where	they	act	as	secreted	hormones	of	the	
endocrine glands, the stanniocalcins in mammals are thought to have an autocrine or 
paracrine role (Chang et al. 1995), although their function as a circulating hormone 
has also been suggested (James et al. 2005). The possibility of an intracellular role 
of STC-1 has been suggested because STC-1 is localized in the inner mitochondrial 
membrane which regulates cellular metabolism (McCudden et al. 2002, Westberg 
et al. 2007). It would be interesting to investigate the relationship and interactions 
between stanniocalcins in the tumor cells and the extracellular matrix, in order to 
gain a better understanding of the function of stanniocalcins in tumor cell survival.
Stanniocalcins	have	also	been	shown	to	play	a	role	in	inflammation	(Iyer	et al. 
1999). In an experiment on hypoxic preconditioning in mice, they upregulated the 
expression of STC-1 in the brain via IL-6-dependent signalling (Westberg et al. 
2007);	this	indicates	that	inflammatory	cytokines,	particularly	of	the	IL-6	family,	
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may contribute to STC-1 levels in tumors (Knüpfer and Preiss 2007, Underhill-Day 
and Heath 2006). 
All	of	these	findings	give	reason	to	assume	that	stanniocalcins	participate	 in	
tumor dormancy by facilitating tumor cells to enter and remain in a quiescent 
state as a micrometastatic lesion. In such a lesion, the tumor cells are in balance 
with cell proliferation and apoptosis, thus contributing to angiogenic dormancy, 
or dormancy related to immunosurveillance. 
ER  
The relationship of ER to stanniocalcins is discussed here, while the role of ER in 
breast cancer progression and tumor dormancy is described more thoroughly in the 
previous section (Study IV). In this study, ER expression was also found to associate 
with late recurrence of breast cancer. The expression of ER did not correlate with 
STC-1 or STC-2 expression in the primary cancers in this tumor material, but a 
positive correlation was found between ER and STC-1 in the recurrent/metastatic 
tumors.
STC-2 has been found to be an estrogen-responsive gene. Yamamura et al. (2004) 
found that expression of STC-2 was associated with a more favorable prognosis in 
hormone	receptor-positive	(ER	and/or	PR)	tumors	treated	with	adjuvant	hormone	
therapy, whereas STC-2 expression did not have any impact on the prognosis of 
patients with hormone-negative tumors. The expression of STC-1 in breast cancer 
is less dependent on steroid hormones. 
STUDY II 
In Study II, the markers maspin, Bcl-2 and p53 were investigated. The association 
of these markers with tumor dormancy contradicted their presumed functional 
properties to some extent. The maspin and p53 with tumor suppressive properties 
were associated with early tumor relapse in this study. On the other hand, the Bcl-
2 as an antiapoptotic factor, presumed to support metastatic growth and act as a 
dormancy-inhibiting factor, was associated with late tumor recurrence. 
MASPIN
In	this	study,	cytoplasmic	maspin	correlated	significantly	with	early	tumor	relapse.	
The	mean	expression	of	cytoplasmic	maspin	was	significantly	higher	in	the	early-
metastasizing breast cancers than in the late-metastasizing ones. The proportion 
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of tumors with nuclear positivity for maspin in this material was lower than the 
proportion of cytoplasmic maspin-positive tumors. Additionally, the nuclear maspin 
positivity tended to be stronger in the late-relapsing tumors. This indicates that 
cytoplasmic maspin or lack of nuclear maspin was associated with early progression 
of cancer. Maspin expression has been associated with both favorable outcome 
(Maass et al. 2001, Mohsin et al. 2003), as well as poor prognosis in breast cancer 
(Umekita et al. 2002, Yoshihisa et al. 2002). It has previously been proposed that 
these controversial results could be related to the subcellular location of maspin, and 
that nuclear localization is essential for maspin to inhibit tumor growth (Goulet et al. 
2011). As a tumor-suppressing factor, and as a serine protease inhibitor (Bailey et al. 
2006) maspin should prevent tumors from metastasizing. It should prevent primary 
tumor invasion through the basement membrane, through extracellular matrix, and 
through	blood	and	lymph	vessel	walls.	The	findings	of	this	study	demonstrate	that	
the anti-tumor dormancy role of maspin is related to its cytoplasmic localization.
BCL-2
The	levels	of	Bcl-2	staining	were	significantly	lower	in	the	early-relapsing	cancers,	
both in primary tumors and their metastases, compared to late-recurring tumors. 
As an inhibitor of apoptosis, Bcl-2 expression in breast cancer should inhibit 
apoptosis, and therefore predict a worse outcome and function as an anti-tumor-
dormancy factor (Pantel 2009). In contrast, in line with the results in this study, 
it	is	well	known	that	the	expression	of	Bcl-2	in	breast	cancer	signifies	a	favorable	
prognosis (Gasparini et al. 1995, Lê et al. 1999, Neri et al. 2006). This apparently 
paradoxical favorable prognostic value of Bcl-2 expression may be explained partly 
by the pro-apoptotic activity of other members of the Bcl-2 family (Neri et al. 2006, 
Takayama et al. 1995), the inhibitory activity of Bcl-2 on cell proliferation (Knowlton 
et al.	1998),	or	the	estrogen-inducibility	of	Bcl-2	expression	(Krajewski	et al. 1999). 
The strong association of Bcl-2 with ER in this study is in accordance with 
previous results (van Slooten et al. 1996, Lê et al. 1999). Bcl-2 is present in the 
normal breast; it may thus have a role in normal cyclical breast development, and 
may be controlled by an estrogen-dependent transcriptional pathway (Gasparini 
1995, Leek 1994).
P53
p53	expression	 in	 this	 study	 signified	 early	 tumor	 relapse.	Many	 studies	have	
investigated the association between p53 gene over-expression and the clinical 
outcome of breast cancer. Most of these studies show a poorer overall and disease-
88
JOENSUU – Tumor Dormancy In Breast Cancer 
free survival for breast cancer patients with p53 mutation (Elledge and Allred 1998). 
The	p53	expression	in	this	study	did	not	significantly	differ	between	primary	tumors	
and the metastases. This has also been shown by others (Shimizu et al. 2000).
The	expression	of	p53	in	this	study	associated	significantly	with	cytoplasmic	
maspin, both in primary tumors and in their recurrences. p53 regulates the 
expression of the maspin gene (Zou et al. 2000). Both positive correlation (Umekita 
et al.	2002)	and	negative	correlation	(Hojo	et al. 2001) between maspin and p53 have 
been reported.  p53 is encoded by the TP53 gene known as a tumor suppressor gene. 
p53 has many mechanisms of anticancer function, and it plays a role in apoptosis, 
genomic stability, and inhibition of angiogenesis. When the TP53 is damaged, tumor 
suppression is severely reduced. The mutated p53 protein, as in this tumor material, 
can be measured by IHC, and the high expression of mutated p53 is associated with 
decreased apoptotic and antiproliferative function. The mutant p53 protein itself can 
inhibit normal p53 function. The mutant p53 measured in this study thus belongs to 
the factors that support metastatic progression and escape from tumor dormancy. 
In	 this	 study,	 p53	positivity	 also	 associated	 significantly	with	 other	 factors	
contributing to early tumor relapse, i.e. CK5, cytoplasmic maspin and Ki67 positivity.
In conclusion, the main result in Study II is that cytoplasmic maspin and p53 
positivity, together with low Bcl-2 and ER expression, are associated with early 
tumor recurrence. 
STUDY III
The expression of polycomb protein and oncogene Bmi-1, proto-oncogene c-myc, 
and transcription factor Snail were analysed in Study III. As postulated, stem-cell 
markers, all of which are members of the hedgehog signalling pathway (Liu et al. 
2006), are believed to suppress tumor dormancy. In these tumor series, the c-myc 
and Snail expression were not clearly associated with early or late tumor recurrence. 
C-myc	was	associated	significantly	with	axillary	node	positivity	 in	breast	cancer	
patients; this is also in agreement with other studies (Lê et al. 1999). 
Only Bmi-1 expression in this study was associated with the time of tumor 
recurrence. The highest expression was seen in the metastases of the latest recurring 
cancers, indicating that Bmi-1 expression correlates with a slow initial progression of 
cancers. These results suggest that metastases, in contrast to primary tumors, arise 
from tumor cells that have retained their stem cell properties. Bmi-1 expression has 
been associated with both favorable and poor prognosis in breast cancer. In their 
study, Wang et al. (2012) showed that Bmi-1 status correlated with high tumor grade, 
basal-like phenotype, and decreased 5-year overall survival of the patients. Silva 
et al. (2007) demonstrated that the circulating Bmi-1 mRNA is a poor prognostic 
factor in breast cancer patients. Bmi-1 protein expression in breast cancer tissue has 
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also been associated with favorable overall survival, but only in ER-positive patients 
(Choi et al.	2009).	In	this	tumor	material,	Bmi-1	positivity	correlated	significantly	
with ER positivity, in both primary tumors and metastases. 
Al-Hajj	et al.	 (2003)	were	the	first	to	describe	a	cancer	stem	cell	population	
in human breast cancers; these cancer stem cells displayed increased expression 
of Bmi-1 (Liu et al. 2006).  The Bmi-1 expression in these tumors may therefore 
reflect	stem	cell	properties,	enabling	the	tumor	cells	to	remain	inactive	for	a	long	
time and to maintain their self-renewal and tumor-initiating capability. Later, in 
appropriate circumstances, they may begin metastatic growth. 
In	figure	14	the	imaginary	pathway-schema	of	disseminated	cancer	cells	and	
tumor dormancy as a component of breast cancer progression is illustrated.
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Figure 14. Tumor dormancy as a component of cancer progression
Cancer cells that have undergone malignant genetic or epigenetic changes have acquired motile and 
cooperation with stromal cells, can degrade the extracellular matrix (ECM) and the vascular walls and 
intravasate (through arterial or lymphatic routes). Tumor cells that are arrested in the vasculature of the 
etc., where they metastasize). Tumor cells in the bone marrow have the potential to become secondary 
lesions, and they can also carry the information about the future progression of the disease. Tumor cells can 
arrest in lymph nodes or in the target organ vasculature where they can extravasate into organ parenchyma.
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Possible fates of tumor cells after extravasation
Intra- or extra-vascularly lodged tumor cells in organ parenchyma, in the bone marrow or lymph 
nodes have four alternative fates: 1) they die (the vast majority of cells undergo apoptosis), 2) they 
can enter a state of quiescence or dormancy, either as a single solitary cell (G0-G1 arrest), or 3) as a 
micrometastatic lesion that undergoes proliferative expansion and cannot recruit a vascular bed, or 
4) they can resume proliferation and form growing micrometastases. With time, the minimal 
(angiogenic dormancy) can also begin to proliferate and switch to growing micrometastases 
the steps in tumor progression according to their functional properties. Adapted with permission 
from Aguirre-Ghiso and Nat Rev Cancer (Aguirre-Ghiso 2007).
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CONCLUDING REMARKS
The aim of these four studies was to investigate the relationship between the 
expression of different proteins and the clinicopathological parameters in the tumors 
of breast cancer patients in respect to tumor dormancy. The studies of this thesis 
focus on metastatic tumor dormancy, in other words, the latency period between 
detection of the primary tumor and manifestation of the recurrent/metastatic lesion. 
The results were more in accordance with the results of clinical studies in which 
protein or gene expression has been evaluated in the tumor tissue of breast cancer 
patients, than with the knowledge of the functional properties of the markers 
obtained from in vitro and in vivo experimental models. This is understandable 
because the functioning of the proteins in the tumor tissue of patients is differentially 
controlled	by	signals	from	the	surrounding	stromal	tissue,	including	inflammatory	
cells,	 immunological	and	hormonal	 influence,	and	the	effects	of	 the	treatment,	
compared to laboratory conditions. 
In this study, the markers that correlated most strongly with the late relapse 
of the tumors, i.e., to tumor dormancy, were stanniocalcins, ER, Bcl-2 and Bmi-1, 
and	the	IHC	phenotype	‘luminal	A’.	Markers	that	associated	significantly	with	early	
tumor relapse were HER2, Ki67, maspin, p53, and CK5.  
This work showed that the expression of proteins measured by IHC differs during 
the different developmental stages of breast cancer. It is nevertheless extremely 
difficult	to	deduce	the	phenomenon	of	tumor	dormancy	from	IHC	staining	results	
to cancer progression. 
Currently,	the	selection	of	patients	who	would	benefit	from	additional	systemic	
therapies after surgical resection is based on their statistical risk of developing tumor 
recurrence. The statistical risk is based on the clinicopathological parameters and 
the IHC evaluation of ER, PR, HER2 and Ki67 expression of the primary tumor 
tissue, without knowledge of whether they actually harbor DTCs or CTCs. This 
uncertainty may lead to over-treatment. 
DTCs/CTCs are cells which can potentially initiate new growth and escape from 
tumor dormancy. In future it is essential to continue the efforts to elucidate the 
entire chain in cancer progression, i.e., from manifestation of the primary tumor 
to initiation of the recurrent tumor, and the clinically dormant state between these. 
So, in addition to the characterization of the primary tumor, it is essential to include 
DTCs/CTTs in the analysis. This information is also important for the design of 
clinical	trials	which	apply	biological	therapies	directed	at	specific	targets.		
In this study, the most interesting proteins related to late relapse of tumors 
were ones which were enriched in metastases that manifested 10 years after the 
primary treatment, namely stanniocalcins, ER, bcl-2 and Bmi-1. Especillay Bm-1, 
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which has stem cell properties, appears to be a promising  marker in CTCs/DTCs 
to be screened from the blood or BM of breast cancer patients.
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